Methods of administering genetically modified B cells for in vivo delivery of therapeutic agents

JP2023548118A5Inactive Publication Date: 2024-11-06IMMUSOFT CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526012
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-29
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for administering engineered B cells to the central nervous system (CNS) face challenges due to the immunological privilege of the CNS, limiting the effectiveness of therapeutic agents for chronic diseases and disorders.

Method used

Direct administration of genetically modified B cells to the CNS, such as through intrathecal, intraventricular, or intracisternal injection, for in vivo production of therapeutic agents like iduronidase (IDUA), optimized through suboptimal single dose concentrations and sequential dosing to achieve long-term survival and expression.

Benefits of technology

The method enables long-term survival and transgene expression of B cells in the CNS, resulting in pharmacological effects and effective treatment of chronic diseases associated with enzyme deficiencies, such as mucopolysaccharidosis type I (MPS I).

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are methods for administering engineered B cells to produce a therapeutic agent in vivo. In various embodiments, the engineered B cells are administered directly to the central nervous system (CNS). The compositions and methods disclosed herein can be used for enzyme replacement therapy, for example, to treat diseases or disorders associated with lysosomal storage dysfunction via the production of iduronidase (IDUA). The present invention provides, for example, a method for administering genetically modified B cells to a subject for the in vivo production of a therapeutic agent, comprising administering one or more doses of genetically modified B cells to the subject's central nervous system (CNS).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Sequence Listing Statement This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63 / 107,992, filed October 30, 2020, which is incorporated herein by reference in its entirety.

[0002] Sequence Listing Statement The Sequence Listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference. The text file containing the Sequence Listing is named IMCO_009_01WO_ST25.txt. The text file is approximately 10 KB, was created on October 28, 2021, and has been submitted electronically via EFS-Web.

[0003] Technical Field The present disclosure relates generally to methods for administering engineered cells to a subject to produce a therapeutic agent, e.g., a therapeutic protein. Methods for administering engineered B cells to the central nervous system are specifically disclosed. [Background technology]

[0004] background Cell therapy in the CNS (e.g., brain) presents unique challenges due to the immunological privilege of the CNS. For this reason, previous attempts at local administration of B cells have not been widely extended to the CNS (e.g., brain). Summary of the Invention [Means for solving the problem]

[0005] overview The present disclosure provides methods for administering genetically modified (engineered) B cells directly to central nervous system (CNS) tissues in a subject to treat chronic diseases and disorders affecting such tissues.

[0006] In certain aspects, the present disclosure provides a method of administering genetically modified B cells to a subject for the in vivo production of a therapeutic agent, the method comprising administering one or more doses of the genetically modified B cells to the central nervous system (CNS) of the subject.

[0007] In some embodiments, the administering step comprises injection into the cerebrospinal fluid (CSF) of the subject.

[0008] In some embodiments, the administering step comprises intracisternal injection.

[0009] In some embodiments, the administering step comprises intrathecal injection.

[0010] In some embodiments, the administering step comprises intracerebroventricular injection (ICV).

[0011] In some embodiments, intraventricular injection (ICV) is performed in one or more cavities of the brain.

[0012] In some embodiments, the one or more brain cavities are lateral ventricles.

[0013] In some embodiments, the one or more brain cavities is the third ventricle.

[0014] In some embodiments, the one or more brain cavities is the cerebral aqueduct.

[0015] In some embodiments, the one or more brain cavities is the fourth ventricle.

[0016] In some embodiments, the therapeutic agent produced by the genetically modified B cells is iduronidase (IDUA).

[0017] In some embodiments, the dose comprises genetically modified B cells at a suboptimal single dose concentration, the suboptimal single dose concentration being determined by the steps of: (i) testing multiple single doses of the modified B cells; (ii) determining an optimal single dose concentration of the modified B cells, wherein increasing dosages of the modified B cells present in the single dose concentration of the modified B cells result in production of the therapeutic agent; (iii) testing multiple suboptimal single dose concentrations of the modified B cells; and (iv) determining a suboptimal single dose of the modified B cells, wherein the resulting dosages result in greater than linear increase over lower dosages, and the suboptimal single dose concentration is less than or equal to about one-half or about one-third the dose of the optimal single dose concentration.

[0018] In some embodiments, the administering step optionally comprises one or more sequential doses of genetically modified B cells.

[0019] In some embodiments, the subject is a mammal.

[0020] In some embodiments, the subject is a human.

[0021] In some embodiments, the genetically modified B cells are autologous to the subject.

[0022] In some embodiments, the genetically modified B cells are allogeneic to the subject.

[0023] In some embodiments, the therapeutic agent is a protein.

[0024] In some embodiments, the protein is an enzyme.

[0025] In some embodiments, the genetically modified B cells are CD20-, CD38+ and CD138+.

[0026] In some embodiments, the genetically modified B cells are CD20-, CD38+ and CD138-.

[0027] In some embodiments, genetically modified B cells were prepared using the Sleeping Beauty transposon to express a therapeutic agent in B cells.

[0028] In some embodiments, the genetically modified B cells are prepared using recombinant viral vectors to express therapeutic agents in the B cells.

[0029] In some embodiments, the recombinant viral vector encodes a recombinant retrovirus, lentivirus, adenovirus, or adeno-associated virus. In some embodiments, the genetically modified B cells are prepared by gene editing of the genome of the B cell or by targeted integration of a polynucleotide sequence encoding a therapeutic agent into the genome of the B cell.

[0030] In some embodiments, targeted integration comprises zinc finger nuclease-mediated gene integration, CRISPR-mediated gene integration or gene editing, TALE-nuclease-mediated gene integration, or meganuclease-mediated gene integration.

[0031] In some embodiments, targeted integration of the polynucleotide is achieved by homologous recombination.

[0032] In some embodiments, targeted integration involves viral vector-mediated delivery of a nuclease capable of inducing DNA cleavage at the target site.

[0033] In some embodiments, the nuclease is a zinc finger nuclease, a Cas nuclease, a TALE-nuclease, or a meganuclease.

[0034] In some embodiments, the genetically modified B cells comprise a polynucleotide having a sequence identical to SEQ ID NO:1.

[0035] In some embodiments, the genetically modified B cells comprise a polynucleotide having a sequence that is at least about 85% identical to SEQ ID NO:1, or at least about 90%, 95%, 96%, 97%, 98%, 99%, or more than 99% identical to SEQ ID NO:1.

[0036] In some embodiments, the genetically modified B cells are manipulated on the second or third day after initiation of culture.

[0037] In some embodiments, the genetically modified B cells are engineered using methods including electroporation.

[0038] In some embodiments, the genetically modified B cells are harvested for administration to a subject on day 4, 5, 6, or 7 of culture after manipulation.

[0039] In some embodiments, the genetically modified B cells are harvested after 8 days or more in culture following manipulation for administration to a subject.

[0040] In some embodiments, the genetically modified B cells are harvested for administration to a subject on or before day 10 in culture after manipulation.

[0041] In some embodiments, the collected genetically modified B cells do not produce significant levels of inflammatory cytokines.

[0042] In some embodiments, the genetically modified B cells are harvested at a point in culture when it has been determined that they do not produce significant levels of inflammatory cytokines.

[0043] In some embodiments, the genetically modified B cells are grown in a culture system containing each of IL-2, IL-4, IL-10, IL-15, IL-21, and multimerized CD40 ligand throughout the entire culture period, both before and after manipulation.

[0044] In some embodiments, the multimerized CD40 ligand is a HIS-tagged CD40 ligand that is multimerized using an anti-his antibody.

[0045] In some embodiments, the method includes expanding the genetically modified B cells prior to administering to the subject.

[0046] In some embodiments, the final population of expanded genetically modified B cells demonstrates a high degree of polyclonality.

[0047] In some embodiments, any particular B cell clone in the final population of expanded genetically modified B cells comprises less than 0.2% of the total B cell population.

[0048] In some embodiments, any particular B cell clone in the final population of expanded genetically modified B cells comprises less than 0.05% of the total B cell population.

[0049] In some embodiments, the genetically modified B cells comprise a polynucleotide encoding a human DHFR gene that has increased resistance to methotrexate.

[0050] In some embodiments, the human DHFR gene with increased resistance to methotrexate contains a leucine to tyrosine substitution at amino acid 22 and a phenylalanine to serine substitution at amino acid 31.

[0051] In some embodiments, the method comprises treating the genetically modified B cells with methotrexate prior to collection for administration.

[0052] In some embodiments, the methotrexate treatment is between 100 nM and 300 nM.

[0053] In some embodiments, the methotrexate treatment is 200 nM.

[0054] In some embodiments, the genetically modified B cells, upon administration to a subject, migrate throughout tissues within the central nervous system (CNS).

[0055] In some embodiments, administration of the genetically modified B cells to a subject results in a reduction of glycosaminoglycans (GAGs) in various tissues of the subject.

[0056] In some embodiments, administration of the genetically modified B cells to a subject results in a reduction of GAGs in tissues within the central nervous system (CNS).

[0057] In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks.

[0058] In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0059] In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks.

[0060] In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0061] In some embodiments, the subject has a disease or disorder associated with lysosomal storage dysfunction.

[0062] In some embodiments, the disease or disorder associated with lysosomal storage dysfunction is caused by a deficiency in the enzyme alpha-L-iduronidase (IDUA).

[0063] In some embodiments, the subject has Mucopolysaccharidosis type I (MPS I).

[0064] In some embodiments, administration of the genetically modified B cells treats a disease or disorder associated with lysosomal storage dysfunction in a subject.

[0065] In some embodiments, administration of the genetically modified B cells treats MPS I in the subject.

[0066] Other aspects and advantages of the present invention will become readily apparent from the following detailed description of the invention.

[0067] For the purpose of illustrating the present disclosure, certain embodiments of the present disclosure are depicted in the drawings. However, the present disclosure is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings. [Brief explanation of the drawings]

[0068] [Figure 1] Figure 1 shows the analysis of IDUA activity from whole brain tissue of mice in which engineered B cells were administered directly into the central nervous system.

[0069] [Figure 2] Figure 2 shows the analysis of GAGs from brain tissue of mice in which engineered B cells were administered directly into the central nervous system.

[0070] [Figure 3] Figure 3 shows bioluminescence imaging of NSG mice injected ICV with LUC-transferred human B cells. Mice were imaged biweekly (IVIS). Luminescence intensity is shown on the scale.

[0071] [Figure 4] FIG. 4 shows a line graph of the bioluminescence imaging results from FIG. DETAILED DESCRIPTION OF THE INVENTION

[0072] Detailed Description Enzyme deficiencies can result in chronic diseases and disorders. Enzyme replacement therapy is the current method for treating such diseases and disorders by direct injection of exogenous enzymes (therapeutic agents) to counteract the enzyme deficiency. However, this treatment method has drawbacks. The effectiveness of injected recombinant therapeutic proteins is limited by the finite half-life of the protein and may provide suboptimal tissue penetration by the therapeutic agent. The present disclosure addresses some of the limitations of enzyme replacement therapy in order to more effectively treat certain diseases and disorders associated with enzyme deficiencies.

[0073] The use of differentiated B cell compositions for long-term in vivo expression of transgenes has been identified as a promising strategy for the treatment of various diseases and disorders involving enzyme deficiencies. However, methods for administering modified B cells for the delivery of therapeutic agents have not yet been described to achieve therapeutically effective levels of the agent in vivo. The present disclosure provides methods for administering genetically modified (engineered) B cells, including expression of a transgene encoding modified human DHFR for the production of iduronidase (IDUA) in vivo, to treat chronic diseases and disorders, particularly those associated with lysosomal storage dysfunction, by administering the engineered B cells directly to the central nervous system (CNS).

[0074] The embodiments described herein relate, in part, to the inventors' surprising discovery that administration of differentiated B cell compositions by direct injection into the CNS resulted in long-term B cell survival and transgene expression in the CNS. Furthermore, the expressed transgene produced pharmacological effects in the brain. definition

[0075] To facilitate the understanding of the present invention, several terms and abbreviations, when used herein, are defined as follows:

[0076] As used herein, the singular forms "a," "an," and "the" include plural aspects unless the context clearly dictates otherwise. For example, reference to "a vector" includes a single vector, as well as two or more vectors; reference to "a cell" includes one cell, as well as two or more cells; etc.

[0077] The term "and / or," when used in the context of a series of two or more items, means that any one of the listed items can be used by itself or in combination with any one or more of the listed items. For example, the phrase "A and / or B" is intended to mean either or both of A and B, i.e., A alone, B alone, or a combination of A and B. The phrase "A, B, and / or C" is intended to mean A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0078] Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers, but not the exclusion of any other element or integer or group of elements or integers.

[0079] "Consisting of" means inclusive and limited to everything that follows the phrase "consisting of." Thus, the phrase "consisting of" indicates that the listed elements are required or essential, and that no other elements may be present. "Consisting essentially of" means including any elements listed after this phrase, and is limited to other elements that do not interfere with or contribute to the activity or action identified in this disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or essential, but that other elements are optional and may or may not be present depending on whether they affect the activity or action of the listed elements.

[0080] Reference to the term "for example" is intended to mean "for example, but not limited to," and therefore should be understood to be merely an example of a particular embodiment, but should in no way be construed as being a limiting example. Unless otherwise indicated, use of "for example" is intended to expressly indicate that other embodiments are contemplated and encompassed by the present invention.

[0081] References throughout this specification to "an embodiment" or "one embodiment" or "an embodiment" or "some embodiments" or "a particular embodiment" mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" or "in a particular embodiment" or "some embodiments" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0082] An "increased" or "enhanced" amount is typically a "statistically significant" amount and can include an increase that is 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50-fold or greater (e.g., 100, 500, 1000-fold) (including all integers and decimal points therebetween and greater than 1, e.g., 2.1, 2.2, 2.3, 2.4, etc.) of the amounts or levels described herein. Similarly, a "decreased" or "reduced" or "less" amount is typically a "statistically significant" amount and can include a decrease that is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 times or more (e.g., 100, 500, 1000 times) (including all integers and decimal points therebetween and greater than 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.) of the amounts or levels described herein.

[0083] As used herein, "as needed" or "as needed" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where said event or circumstance occurs and cases where it does not occur.

[0084] As used herein, "substantially" or "essentially" means an abundant or significant amount, quantity, size; nearly entirely or completely; for example, 95% or more of some given quantity.

[0085] The terminology used herein is intended only to describe specific embodiments and is not intended to be limiting.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.Any materials and methods similar or equivalent to those described herein can be used to implement the present invention.The implementation of the present invention can use conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology that are within the skill of the art. Such techniques are described in Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al, 1989) Cold Spring Harbor Press;Oligonucleotide Synthesis (MJ. Gait, ed., 1984);Methods in Molecular Biology, Humana Press;Cell Biology: A Laboratory Notebook (J .E. Cellis, ed., 1998) Academic Press;Animal Cell Culture (RI Freshney, ed., 1987);Introduction to Cell and Tissue Culture (JP Mather and PE Roberts, 1998) Plenum Press;Cell and Tissue Culture: Laboratory Procedures (A. Doyle, JB Griffiths, and DG Newell, eds., 1993- 1998) J. Wiley and Sons;Methods in Enzymology (Academic Press, Inc.);Handbook of Experimental Immunology (D.M. Weir and CC. Blackwell, eds.);Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987);Current Protocols in Molecular Biology (F .M. Ausubel et al, eds., 1987);PCR: The Polymerase Chain Reaction, (Mullis et al, eds., 1994);Current Protocols in Immunology (JE Coligan et al, eds., 1991); (Wiley and Sons, 1999);Immunobiology (CA. Janeway and P. Travers, 1997);Antibodies (P. Finch, 1997);Antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989);Monoclonal antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989);Monoclonal antibodies: a practical approach (P. Oxford University Press, 2000);Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999);The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995); (VT DeVita et al, eds., JB Lippincott Company, 1993).

[0086] The terms "in vitro," "ex vivo," and "in vivo" are intended herein to have their ordinary scientific meaning. Thus, for example, "in vitro" is meant to refer to an experiment or reaction performed with isolated cellular components, such as an enzymatic reaction carried out in a test tube using appropriate substrates, enzymes, donors, and buffers / cofactors as needed. "Ex vivo" is meant to refer to an experiment or reaction performed using functional organs or cells removed from or propagated independently of an organism. "In vivo" is meant to refer to an experiment or reaction performed within a living organism in its normal, intact state.

[0087] As used herein, "mammal" includes both humans and domestic animals, such as laboratory animals and domestic pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, and rabbits), and non-domestic animals, such as wild animals.

[0088] As used herein, "subject" includes any animal that exhibits a disease or symptom that can be treated with the agent of the present invention, or that is at risk of exhibiting a disease or symptom.Suitable subjects include experimental animals (e.g., mice, rats, rabbits, or guinea pigs), farm animals, and domestic animals or pet animals (e.g., cats or dogs).Non-human primates are also included, preferably human patients.

[0089] As used herein, "proliferation" or "expansion" refers to the ability of a cell or population of cells to increase in number.

[0090] As used herein, "differentiate" or "differentiated" refers to the process and conditions by which immature (unspecialized) cells acquire the characteristics of becoming mature (specialized) cells, thereby acquiring a particular morphology and function. Stem cells (unspecialized) are often exposed to various conditions (e.g., growth factors and morphogenetic factors) to induce their specified lineage commitment, or differentiation. For example, memory B cells that transition into plasma cells are differentiated.

[0091] As used herein, the term "CD20-, CD38+, and CD138+" is used to refer to cells that express both the CD38 and CD138 surface markers and do not express the CD20 surface marker, where "+" indicates presence and "-" indicates absence. Thus, alternatively, the term "is CD20-, CD38+, and CD138-" is used to refer to cells that express the CD38 surface marker but do not express both the CD38 and CD138 surface markers.

[0092] B cells are specific immune cells that act as antigen-presenting cells (APCs) and internalize antigens. Antigens are taken up and processed by B cells via receptor-mediated endocytosis. Antigens are processed into antigenic peptides, loaded onto MHC II molecules, and presented on the extracellular surface of B cells to CD4+ T helper cells. These T cells bind to the MHC II / antigen molecules, causing B cell activation. Upon stimulation by T cells, activated B cells begin to differentiate into more specialized cells. Germinal center B cells can differentiate into long-lived memory B cells or plasma cells. Furthermore, secondary immune stimulation can result in memory B cells that give rise to additional plasma cells. The formation of plasma cells from either memory or non-memory B cells is preceded by the formation of precursor plasmablasts, which eventually differentiate into plasma cells that produce large amounts of antibodies (see, e.g., Trends Immunol. 2009 June; 30(6): 277-285; Nature Reviews, 2005, 5:231-242). Plasmablasts secrete more antibodies than B cells but less than plasma cells. They divide rapidly and continue to internalize and present antigens to T cells. Plasmablasts have the ability to migrate to sites of chemokine production (e.g., in the bone marrow), thereby enabling them to differentiate into long-lived plasma cells. Finally, plasmablasts can either remain plasmablasts for several days and then die, or they can terminally differentiate into mature, fully differentiated plasma cells. Specifically, plasmablasts, which can home to tissues containing plasma cell survival niches (e.g., in the bone marrow), can replace resident plasma cells to become long-lived plasma cells that can continue to secrete high levels of proteins for several years. Terminally differentiated plasma cells typically do not express common pan-B cell markers, such as CD19 and CD20, and express relatively few surface antigens. Plasma cells express CD38, CD78, CD138, and interleukin-6 receptor (IL-6R), but lack CD45 expression; these markers can be used, for example, by flow cytometry, to identify plasma cells.CD27 is also a good marker for plasma cells, as naive B cells are CD27-, memory B cells are CD27+, and plasma cells are CD27++. Memory B cell subsets can also express surface IgG, IgM, and IgD, but plasma cells do not express these markers on the cell surface.CD38 and CD138 are expressed at high levels on plasma cells (see Wikipedia, The Free Encyclopedia., "Plasma cell" Page Version ID: 404969441; Date of last revision: 30 December 2010 09:54 UTC, retrieved January 4, 2011; see also: Jourdan et al. Blood. 2009 Dec 10;114(25):5173-81; Trends Immunol. 2009 June; 30(6): 277-285; Nature Reviews, 2005, 5:231 - 242; Nature Med. 2010, 16: 123-129; Neuberger, MS; Honjo, T.; Alt, Frederick W. (2004). Molecular biology of B cells. Amsterdam: Elsevier, pp. 189-191;Bertil Glader; Greer, John G; John Foerster; Rodgers, George G.; Paraskevas, Frixos (2008). Wintrobe's Clinical Hematology, 2-Vol. Set. Hagerstwon, MD: Lippincott Williams & Wilkins. pp. 347;Walport, Mark; Murphy, Kenneth; Janeway, Charles; Travers, Paul J. (2008). Janeway's immunobiology. New York: Garland Science, pp. 387-388; Rawstron AC (May 2006). "Immunophenotyping of plasma cells". Curr Protoc Cytom).

[0093] B cells used in the methods described herein include pan-B cells, memory B cells, plasmablasts, and / or plasma cells. In one embodiment, the modified B cells are memory B cells. In one embodiment, the modified B cells are plasmablasts. In one embodiment, the modified B cells are plasma cells.

[0094] As used herein, the term "isolated" is used to refer to a molecule or cell that has been removed from its natural environment. As used herein, the term "non-naturally occurring" is used to refer to an isolated molecule or cell that possesses a structure that is significantly different from its counterpart found in nature.

[0095] As used herein, a composition containing a "purified cell population" or "purified cell composition" means that at least 30%, 50%, 60%, typically at least 70%, and more preferably 80%, 90%, 95%, 98%, 99% or more of the cells in the composition are of the identified type.

[0096] In this description, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the recited range, and fractions thereof (e.g., tenths and hundredths of integers), as appropriate, unless otherwise indicated. The term "about," when immediately preceding a number or numeral, means that the number or numeral is within a range of plus or minus 10%.

[0097] The terms "polynucleotide" or "nucleic acid" are used interchangeably herein to refer to a polymer of nucleotides, which may be mRNA, RNA, cRNA, cDNA, or DNA. The term refers to a polymeric form of nucleotides, typically at least 10 bases in length, either ribonucleotides or deoxynucleotides, or modified forms of either type of nucleotide. The term includes single- and double-stranded forms of DNA.

[0098] The terms "polypeptide," "peptide," or "protein" are used interchangeably herein to refer to a linear series of amino acid residues connected to one another by peptide bonds between the alpha-amino group and the carboxy group of adjacent residues. The amino acid residues are normally in the naturally occurring "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, so long as the desired functional property is retained by the polypeptide.

[0099] As used herein, "antibody" is understood to mean any antigen-binding molecule or molecular complex containing at least one complementarity-determining region (CDR) that specifically binds to or interacts with a target antigen. The term "antibody" includes full-length immunoglobulin molecules containing two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (which may be abbreviated as HCVR, VH, or VH) and a heavy chain constant region. The heavy chain constant region typically contains three domains - CH1, CH2, and CH3. Each light chain contains a light chain variable region (which may be abbreviated as LCVR, VL, VK, VK, or VL) and a light chain constant region. The light chain constant region typically contains one domain (CL1). The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity-determining regions (CDRs), interspersed with more conserved regions, also called framework regions (FRs).

[0100] The terms "host," "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants," "transformed cells," or "engineered cells," including the primary transformed cell and its progeny, regardless of the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. Host cells are any type of cell line that can be used to produce the antigen-binding molecules of the present invention. Host cells include cultured cells, such as, but not limited to, mammalian cultured cells, such as B cells.

[0101] As used herein, the terms "vector" and "construct," used interchangeably, refer to a nucleic acid molecule, preferably a DNA molecule, derived from, for example, a plasmid, bacteriophage, or virus, into which a nucleic acid sequence can be inserted or cloned. A vector may contain one or more unique restriction sites and may be capable of autonomous replication in a defined host cell, including a target cell or tissue or a progenitor cell or tissue thereof, or may be capable of integrating into the genome of a defined host so that cloned sequences can be reproduced. Thus, a vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity whose replication is independent of chromosomal replication, such as a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. A vector may contain any means for ensuring self-replication. Alternatively, a vector may be a vector that, upon introduction into a host cell, integrates into the genome and replicates together with the chromosome(s) into which it is integrated. A vector system may include a single vector or plasmid, the total DNA to be introduced into the genome of a host cell, or two or more vectors or plasmids that together contain a transposon. The choice of vector typically depends on the compatibility of the vector with the host cell into which it will be introduced. The vector may also contain a selectable marker, such as an antibiotic resistance gene, that can be used to select suitable transformants. Examples of such resistance genes are well known to those skilled in the art. In some embodiments, vectors are used to generate the engineered NK cells or engineered macrophage cells of the present invention.

[0102] As used herein, "expression construct" refers to a nucleic acid molecule that includes a coding sequence for a therapeutic protein, a promoter, and may include other regulatory sequences therefor, which cassette may be engineered into a genetic element and / or packaged into the capsid of a viral vector (e.g., a viral particle). Typically, such an expression cassette for generating a viral vector contains the construct sequence described herein flanked by a packaging signal of the viral genome and other expression control sequences, such as those described herein. Any of the expression control sequences may be optimized for a particular species using techniques known in the art, including, for example, codon optimization.

[0103] As used herein, the terms "control element," "control sequence," "regulatory sequence," and the like refer to nucleic acid sequences (e.g., DNA) necessary for the expression of an operably linked coding sequence in a particular host cell. Suitable control sequences for prokaryotic cells include, for example, a promoter and, optionally, cis-acting sequences, such as an operator sequence and a ribosome binding site. Suitable control sequences for eukaryotic cells include transcriptional control sequences, such as promoters, polyadenylation signals, transcriptional enhancers, translational control sequences, such as translational enhancers and internal ribosome binding sites (IRES), nucleic acid sequences that modulate mRNA stability, and targeting sequences that target the product encoded by the transcribed polynucleotide to an intracellular compartment within the cell or to the extracellular environment.

[0104] As used herein, "biological activity" or "biological activity" refers to any response induced in an in vitro assay or in a cell, tissue, organ, or organism (e.g., an animal, mammal, or human) as a result of administering any compound, drug, polypeptide, conjugate, or pharmaceutical composition contemplated herein. Biological activity may refer to agonistic or antagonistic activity. Biological activity may be a beneficial effect; or biological activity may be non-beneficial, i.e., toxic. In some embodiments, biological activity refers to the positive or negative effect that a drug or pharmaceutical composition has on a living subject, e.g., a mammal, e.g., a human. Thus, the term "biologically active" is meant to describe any compound that possesses the biological activity described herein. Biological activity may be assessed by any appropriate means currently known to those skilled in the art. Such assays may be qualitative or quantitative. Those skilled in the art will readily understand the need to use different assays to assess the activity of different polypeptides; this is a routine task for the average researcher. Such assays are often easily performed in a laboratory setting with little or no optimization requirements, and in most cases, commercial kits are available that provide simple, reliable, and reproducible readouts of biological activity for a wide range of polypeptides using a variety of technologies common to most laboratories. If such kits are not available, one of skill in the art can readily design and optimize a homemade biological activity assay for a target polypeptide without undue experimentation; this is a routine aspect of the scientific process.

[0105] "Therapeutic agent" refers to any compound that, when administered in a therapeutically effective amount to a subject (e.g., preferably a mammal, more preferably a human), is capable of providing treatment for a disease or condition, as defined below.

[0106] As used herein, the term "treat" or "treating" or "treatment" encompasses at least an amelioration of symptoms associated with a disease or condition in a patient, where amelioration is used broadly to refer to at least a reduction in a parameter, e.g., the magnitude of a symptom associated with the condition being treated. Thus, "treatment," as used herein, covers the treatment of a disease or condition of interest in a subject, preferably a human, having the disease or condition of interest, including: (i) preventing or inhibiting the development of the disease or condition in a subject, particularly when such a subject has a predisposition to the condition but has not yet been diagnosed with the condition; (ii) inhibiting the disease or condition, i.e., halting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) alleviating the symptoms resulting from the disease or condition. As used herein, the terms "disease," "disorder," and "condition" may be used interchangeably or may differ in that a particular illness, injury, or condition may not have a known causative agent (and thus the etiology has not yet been elucidated) and therefore is not yet recognized as either an injury or a disease, but only as an undesirable state or syndrome, where a more or less specific set of symptoms has been identified by a clinician.

[0107] As used herein, " therapeutically effective " refers to the amount of engineered B cells or therapeutic agent that is sufficient to treat or alleviate, or in some ways reduce, the symptoms associated with disease or disorder, such as enzyme deficiency, protein deficiency, hormone deficiency, inflammation, cancer, autoimmunity or infection.When used in reference to a method, the method is effective enough to treat or alleviate, or in some ways reduce, the symptoms associated with disease or condition.For example, an effective amount in reference to a disease is an amount that is sufficient to block or prevent its onset; or, when disease pathology begins, an amount that is sufficient to alleviate, alleviate, stabilize, reverse or slow down the progression of the disease, or otherwise reduce the pathological consequences of the disease.In either case, the effective amount can be given in a single dose or divided doses.

[0108] The term "combination" refers to either a fixed combination in a single dosage unit form or a kit-of-parts for combined administration, where the engineered B cells and therapeutic agent and combination partner (e.g., another drug, described below, also referred to as a "therapeutic agent" or "co-agent") can be administered independently at the same time or separately within a time interval. In some situations, the combination partners exhibit a cooperative effect, e.g., a synergistic effect. As used herein, the terms "co-administration" or "administration in combination" and the like are meant to encompass the administration of selected combination partners to a single subject (e.g., patient) requiring administration of the selected combination partners, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term "pharmaceutical combination," as used herein, refers to a product resulting from the mixing or combining of more than one active ingredient, and includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" means that the active ingredients, e.g., a compound and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g., a compound and a combination partner, are both administered to a patient as separate entities, either simultaneously, concomitantly, or sequentially, without any specific time limit, wherein such administration provides therapeutically effective levels of the two compounds in the patient's body. The latter also applies to cocktail therapy, e.g., the administration of three or more active ingredients. administering genetically modified B cells

[0109] The present disclosure relates generally to B cells that have been modified via the introduction of nucleic acids to produce a therapeutic agent, and methods of administering the modified B cells. In some embodiments, the terms "engineered B cells," "genetically engineered B cells," "modified B cells," and "genetically modified B cells" are used interchangeably herein to refer to such modified B cells that contain one or more nucleic acids (e.g., transgenes) for producing a therapeutic agent (e.g., a transgene enabling expression of a polypeptide, e.g., a therapeutic polypeptide).

[0110] Thus, the methods for administering modified B cells described herein are useful for long-term in vivo delivery of B cells to the CNS and expression of therapeutic agents in the CNS. The present disclosure provides methods for achieving sufficient enrichment and numbers of cells that produce a therapeutic agent, as well as methods for achieving sufficient levels of a therapeutic agent in the CNS while ensuring the safety of the product.

[0111] As used herein, the phrases "long-term in vivo survival" and "long-term survival" refer to the survival of modified B cells described herein in a subject for 10 days or more following administration. Long-term survival may be measured in days, weeks, or even years. In some embodiments, the majority of modified B cells survive in vivo for 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 days or more following administration. In some embodiments, the majority of the modified B cells survive in vivo for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 weeks or more after administration. In some embodiments, the modified B cells survive in vivo for 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more years. Furthermore, while the modified B cells described herein may survive in vivo for 10 or more days, it is understood that the majority of the modified B cells will survive in vivo for 1, 2, 3, 4, 5, 6, 7, 8, 9 or more days after administration. Thus, it is contemplated that the modified B cells described herein are useful for short-term treatment (e.g., 7 days) and long-term treatment (e.g., 30 days or more) methods. In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks. In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks. In some embodiments, the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0112] In certain aspects, the present disclosure provides a method of administering genetically modified B cells to a subject for the in vivo production of a therapeutic agent, the method comprising administering one or more doses of the genetically modified B cells to the central nervous system (CNS) of the subject.

[0113] In some embodiments, the therapeutic agent produced by the genetically modified B cells is iduronidase (IDUA).

[0114] In some embodiments, the administering step comprises injection into the subject's cerebrospinal fluid (CSF). In some embodiments, the administering step comprises intracisternal injection. In some embodiments, the administering step comprises intrathecal injection. In some embodiments, the administering step comprises intraventricular injection (ICV). In some embodiments, the intraventricular injection (ICV) is performed in one or more brain cavities. In some embodiments, the one or more brain cavities are the lateral ventricles. In some embodiments, the one or more brain cavities are the third ventricle. In some embodiments, the one or more brain cavities are the cerebral aqueduct. In some embodiments, the one or more brain cavities are the fourth ventricle.

[0115] The engineered B cells can be administered as a single dose or multiple doses. In some embodiments, the dose comprises the genetically modified B cells at a suboptimal single dose concentration, the suboptimal single dose concentration being determined by the steps of: (i) testing multiple single doses of the engineered B cells; (ii) determining an optimal single dose concentration of the engineered B cells, where increasing doses of the engineered B cells present in the single dose concentration of the engineered B cells result in production of the therapeutic agent; (iii) testing multiple suboptimal single dose concentrations of the engineered B cells; and (iv) determining a suboptimal single dose of the engineered B cells, where the resulting doses result in greater than linear increase over lower doses, and the suboptimal single dose concentration is less than, or equal to, about one-half or about one-third of the dose at the optimal single dose concentration. In some embodiments, the administering step optionally comprises one or more sequential doses of the genetically modified B cells.

[0116] The optimal dosage and treatment regime for a particular subject can be determined by those skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly. Treatment can also be adjusted after measuring the level of the therapeutic agent (e.g., gene or protein of interest) in a biological sample (e.g., body fluid or tissue sample), which can also be used to evaluate the effectiveness of treatment, and treatment can be adjusted accordingly, increasing or decreasing.

[0117] In some embodiments of the present disclosure, the optimal dose of engineered B cells for a multiple-dose regime can be determined by first determining an optimal single-dose concentration of B cells for a subject, reducing the number of B cells present at the optimal single-dose concentration to provide a suboptimal single-dose concentration of engineered B cells, and administering two or more doses of the suboptimal single-dose concentration of engineered B cells to the subject. In some embodiments, two, three, or more doses of the suboptimal single-dose concentration of engineered B cells are administered to the subject. In some embodiments, administering two, three, or more doses of the suboptimal single-dose concentration of engineered B cells to the subject results in synergistic in vivo production of the therapeutic polypeptide the engineered B cells are engineered to express. In some embodiments, the suboptimal single-dose concentration comprises two, three, four, five, six, seven, eight, nine, ten, or less than the optimal single-dose concentration. In some embodiments, the therapeutic polypeptide is IDUA.

[0118] In one embodiment, a single dose of modified B cells is administered to the subject. In one embodiment, two or more doses of modified B cells are administered sequentially to the subject. In one embodiment, three doses of modified B cells are administered sequentially to the subject. In one embodiment, doses of modified B cells are administered weekly, biweekly, monthly, bimonthly, quarterly, semi-annually, annually, or biennially to the subject. In one embodiment, when the amount of therapeutic agent produced by the modified B cells decreases, a second or subsequent dose of modified B cells is administered to the subject.

[0119] In some embodiments, 10 6 Lower numbers of B cells may be administered, in the range of 1 x 10 / kilogram. In some embodiments, B cells are administered in the range of 1 x 10 / kilogram. 4 , 5×10 4 , 1×10 5 , 5×10 5 , 1×10 6 , 5×10 6 , 1×10 7 , 5×10 7 , 1×10 8 , 5×10 8 , 5×10 9, 1×10 10 , 5×10 10 , 1×10 11 , 5×10 11 or 1×10 12 cells and administered to the subject.

[0120] In some embodiments, a dose of modified B cells is administered to a subject at a certain frequency (e.g., weekly, biweekly, monthly, bimonthly, or quarterly) until a desired amount (e.g., an effective amount) of the therapeutic agent is detected in the subject. In some embodiments, the amount of the therapeutic agent is monitored in the subject. In one embodiment, if the amount of the therapeutic agent produced by the modified B cells falls below the desired amount, a subsequent dose of modified B cells is administered to the subject. In some embodiments, the desired amount is in a range that produces a desired effect. For example, in a method for reducing the amount of glycosaminoglycans (GAGs) in an individual with MPS I, the desired amount of IDUA is an amount that reduces the level of GAGs in a particular tissue compared to the level of GAGs in the absence of IDUA.

[0121] The B cells of the present disclosure can also be administered using any number of matrices. Matrices have been utilized for many years in the context of tissue engineering (see, e.g., Principles of Tissue Engineering (Lanza, Langer, and Chick (eds.), 1997)). The present disclosure utilizes such matrices in the novel context of functioning as artificial lymphoid organs to support and maintain B cells. Thus, the present disclosure can utilize matrix compositions and formulations with demonstrated utility in tissue engineering. Thus, the types of matrices that can be used in the compositions, devices, and methods of the present disclosure are virtually limitless and can include both biological and synthetic matrices. In one particular example, compositions and devices set forth in U.S. Pat. Nos. 5,980,889; 5,913,998; 5,902,745; 5,843,069; 5,787,900; or 5,626,561 are utilized. The matrix must be biocompatible when administered to a mammalian host. The matrix may be formed from natural and / or synthetic materials. The matrix may be non-biodegradable, where a permanent or removable structure, such as an implant, is desired to remain in the animal's body; or it may be biodegradable. The matrix may take the form of a sponge, implant, tube, telfa pad, fiber, hollow fiber, lyophilized component, gel, powder, porous composition, or nanoparticle. Furthermore, the matrix may be designed to allow sustained release of seeded cells or produced cytokines or other active agents. In certain embodiments, the matrix of the present disclosure may be described as a semi-solid scaffold that is flexible and elastic, and permeable to substances such as inorganic salts, aqueous fluids, and dissolved gases, including oxygen.

[0122] A matrix is ​​used herein as an example of a biocompatible material, however, the present disclosure is not limited to matrices, and therefore, whenever the terms matrix(ies) appear, these terms should be interpreted to include devices and other materials that allow cell retention or traversal, are biocompatible, and can allow macromolecular traversal either directly through the material, such as the material itself being a semipermeable membrane, or used in conjunction with a specific semipermeable material.

[0123] In some embodiments, the subject is a mammal, hi some embodiments, the subject is a human.

[0124] In some embodiments, the subject has a disease or disorder associated with lysosomal storage dysfunction. In some embodiments, the disease or disorder associated with lysosomal storage dysfunction is caused by a deficiency of the enzyme alpha-L-iduronidase (IDUA). In some embodiments, the subject has mucopolysaccharidosis type I (MPS I). In some embodiments, administration of the genetically modified B cells treats the subject's disease or disorder associated with lysosomal storage dysfunction. In some embodiments, administration of the genetically modified B cells treats the subject's MPS I.

[0125] In some embodiments, administering B cells genetically modified to express IDUA (IDUA+ B cells) is used to treat a subject having or suspected of having MPS I. In some embodiments, a single optimal dose of IDUA+ B cells is administered to the subject. In some embodiments, two or more doses of IDUA+ B cells are administered to the subject. In some embodiments, the two or more doses of IDUA+ B cells administered to the subject comprise fewer IDUA+ B cells than a single optimal dose of IDUA+ B cells. In some embodiments, two or more doses of IDUA+ B cells are administered to the subject at a dosage of IDUA+ B cells that is less than a maximally effective single dose of IDUA+ B cells. In some embodiments, administering IDUA+ B cells to a subject results in normal levels of IDUA found in healthy control subjects. In some embodiments, administering IDUA+ B cells to a subject results in higher-than-normal levels of IDUA in the subject. In some embodiments, administering IDUA+ B cells to a subject reduces the level of GAG in the subject to normal levels. In some embodiments, administering IDUA+ B cells to a subject reduces the level of GAG in the subject to below the normal level of GAG in the subject. therapeutic agent

[0126] As used herein, "gene of interest" or "gene" or "nucleic acid of interest" refers to a transgene that is expressed in a transfected target cell. Although the term "gene" may be used, this does not imply that it is a gene found in genomic DNA and is used interchangeably with the term "nucleic acid." Generally, a nucleic acid of interest provides a nucleic acid suitable for encoding a therapeutic agent, and may include cDNA or DNA, and may or may not contain introns, but generally does not contain introns. As described elsewhere, a nucleic acid of interest is operably linked to an expression control sequence to effectively express a protein of interest in a target cell. In some embodiments, the vectors described herein may contain one or more genes of interest, and may contain two, three, four, five, or more genes of interest.

[0127] The therapeutic agent delivered by the genetically modified B cells described herein can be a protein. Proteins of interest for use as described herein include any protein that provides a desired activity. In this regard, proteins of interest include, but are not limited to, enzymes.

[0128] In some embodiments, the nucleic acid of interest encodes a protein. In some embodiments, the nucleic acid of interest encodes an enzyme. In some embodiments, the nucleic acid of interest encodes an enzyme for treating a lysosomal storage disorder. In some embodiments, the nucleic acid of interest encodes iduronidase (IDUA).

[0129] In some embodiments, the therapeutic agent produced by the genetically modified B cells is a protein. In some embodiments, the therapeutic agent produced by the genetically modified B cells is an enzyme. In some embodiments, the therapeutic agent produced by the genetically modified B cells is iduronidase (IDUA).

[0130] Thus, the present disclosure provides polynucleotides (isolated, purified, or pure polynucleotides) encoding therapeutic agents (e.g., proteins of interest) of the present disclosure for genetically modifying B cells, vectors (including cloning vectors and expression vectors) containing such polynucleotides, and cells (e.g., host cells) transformed or transfected with polynucleotides or vectors according to the present disclosure. In certain embodiments, polynucleotides (DNA or RNA) encoding proteins of interest of the present disclosure are contemplated. Expression cassettes encoding proteins of interest are also contemplated herein.

[0131] The present disclosure also relates to vectors, particularly recombinant expression constructs, containing the polynucleotides of the present disclosure. In one embodiment, the present disclosure contemplates vectors containing a polynucleotide encoding a protein of the present disclosure together with other polynucleotide sequences that cause or facilitate the transcription, translation, and processing of such protein-coding sequences. Cloning and expression vectors suitable for use with prokaryotic and eukaryotic hosts are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, (1989). Exemplary cloning / expression vectors include cloning vectors, shuttle vectors, and expression constructs that can be based on plasmids, phagemids, phasmids, cosmids, viruses, artificial chromosomes, or any nucleic acid vehicle known in the art that is suitable for amplifying, transferring, and / or expressing the polynucleotides contained therein. Cells and compositions

[0132] In some embodiments, the modified B cells described herein have been activated / differentiated in vitro and transfected to express a therapeutic agent described herein. In some embodiments, the modified B cells described herein have been activated / differentiated in vitro and engineered to express a therapeutic agent described herein (e.g., using a targeted transgene integration approach, e.g., zinc finger nucleases, TALENs, meganucleases, or CRISPR-mediated transgene integration). In some embodiments, the composition comprises B cells that have been differentiated into plasma B cells and transfected or otherwise engineered to express one or more proteins of interest. Target cell populations, e.g., transfected or otherwise engineered, activated B cell populations of the present disclosure, can be administered alone or as a pharmaceutical composition in combination with diluents and / or other components, e.g., cytokines or cell populations.

[0133] In one embodiment, modified B cells engineered to express one or more proteins of interest are harvested from culture following in vitro activation / differentiation at a time when the modified B cells have optimal migratory capacity for a particular chemoattractant. In some embodiments, optimal migratory capacity may be day 7, 8, or 9 of B cell culture. In some embodiments, optimal migratory capacity may be day 5, 6, or 7 of B cell culture after transfection or manipulation. In some embodiments, optimal migratory capacity may be day 8 of B cell culture after transfection or manipulation, or later than day 8 of culture after transfection or manipulation (e.g., day 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or later than day 20). In some embodiments, optimal migratory capacity may be earlier than day 10 of B cell culture. In some embodiments, optimal migratory capacity may be earlier than day 8 of B cell culture after transfection or manipulation. In some embodiments, optimal migratory capacity may be at day 6 or 7 of B cell culture. In some embodiments, optimal migratory capacity may be at day 4 or 5 of B cell culture after transfection or manipulation. In some embodiments, optimal migratory capacity may be before day 9 of B cell culture. In some embodiments, optimal migratory capacity may be before day 7 of B cell culture after transfection or manipulation. In some embodiments, optimal migratory capacity is optimal for homing of the modified B cells to CXCL12. In some embodiments, optimal migratory capacity is optimal for homing of the modified B cells to the bone marrow of a subject receiving one or more doses of the modified B cells. In some embodiments, the B cells are harvested for administration to the subject at about day 7 to about day 9 in culture, at optimal CXCL12 and / or migratory capacity to the subject's bone marrow. In some embodiments, the B cells are harvested for administration to the subject at about day 5 to about day 7 in culture after transfection or manipulation, at optimal CXCL12 and / or migratory capacity to the subject's bone marrow. In some embodiments, B cells are harvested for administration to a subject prior to about day 10 in culture, with optimal CXCL12 and / or migration capacity to the subject's bone marrow.In some embodiments, B cells are collected for administration to a subject at about day 8 in culture after transfection or manipulation, at optimal CXCL12 and / or migratory capacity to the subject's bone marrow. In some embodiments, the optimal migratory capacity is optimal for homing of the modified B cells to CXCL13. In some embodiments, the optimal migratory capacity is optimal for homing of the modified B cells to a site of inflammation in a subject receiving one or more administrations of the modified B cells. In some embodiments, B cells are collected for administration to a subject at about day 6 or about day 7 in culture, at optimal CXCL13 and / or migratory capacity to a site of inflammation in the subject. In some embodiments, B cells are collected for administration to a subject at about day 4 or about day 5 in culture after transfection or manipulation, at optimal CXCL13 and / or migratory capacity to a site of inflammation in the subject. In some embodiments, B cells are collected for administration to a subject at about day 10 in culture, at optimal CXCL13 and / or migratory capacity to a site of inflammation. In some embodiments, B cells are harvested for administration to a subject no earlier than about day 8 in culture after transfection or manipulation, with optimal migratory capacity to sites of CXCL13 and / or inflammation.

[0134] In some embodiments, the optimal migratory capacity is optimal for homing of the modified B cells to both CXCL12 and CXCL13. In some embodiments, the B cells are harvested on day 7 of B cell culture at an optimal migratory capacity for homing to both CXCL12 and CXCL13. In some embodiments, the B cells are harvested on day 5 of B cell culture after transfection or manipulation at an optimal migratory capacity for homing to both CXCL12 and CXCL13.

[0135] In some embodiments, engineered B cells are collected when at least about 20% of the B cells migrate in a chemotaxis assay for a particular chemoattractant. For example, and without limitation, engineered B cells (e.g., producing IDUA) can be collected when at least about 20% of the B cells migrate in a chemotaxis assay for CXCL12. Alternatively, in another non-limiting example, engineered B cells (e.g., producing IDUA) can be collected when at least about 20% of the B cells migrate in a chemotaxis assay for CXCL13. Furthermore, engineered B cells (e.g., producing IDUA) can be collected when at least about 30% of the B cells migrate in a chemotaxis assay to a particular chemoattractant (e.g., CXCL12 or CXCL13), or when at least about 40%, 45%, 50%, 55%, 60%, 65%, or at least about 70% of the B cells migrate in a chemotaxis assay to a particular chemoattractant (e.g., CXCL12 or CXCL13). Furthermore, engineered B cells (e.g., producing IDUA) can be collected when more than 70% of the B cells migrate in a chemotaxis assay. Such chemotaxis assays are known in the art and described herein (see, e.g., Example 6 herein).

[0136] In brief, the cell composition of the present disclosure can comprise a differentiated and activated B cell population that has been transfected and expresses the therapeutic agent described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.Such compositions can include buffers such as neutral buffered saline, phosphate buffered saline, lactated Ringer's solution, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.The composition of the present disclosure is preferably formulated for direct injection into the central nervous system.

[0137] In some embodiments, the modified B cells may comprise a pharmaceutical composition.

[0138] As used herein, the term "pharmaceutical composition" refers to a pharmaceutically acceptable composition, which comprises engineered B cells, and in some embodiments, further comprises a pharmaceutically acceptable carrier.

[0139] As used herein, the term "pharmaceutically acceptable" means approved by a federal or state government regulatory agency or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia, in addition to other formulations, as safe for use in animals, more particularly in humans and / or non-human mammals.

[0140] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically effective excipient" refers to an excipient, diluent, preservative, solubilizer, emulsifier, adjuvant, and / or vehicle with which engineered B cells are administered. Such carriers can be sterile liquids, such as water, and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents. Antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; and agents for adjusting tonicity, such as sodium chloride or dextrose, can also be carriers. Methods for producing compositions in combination with carriers are known to those skilled in the art. In some embodiments, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. See, for example, Remington, The Science and Practice of Pharmacy, 20th ed., (Lippincott, Williams & Wilkins 2003). Unless any conventional media or agent is incompatible with the active compound, its use in the composition is contemplated.

[0141] Pharmaceutical compositions suitable for administration typically contain the active ingredient in combination with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, for example, in ampoules or in multi-dose containers containing a preservative. Formulations for administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and the like. Such formulations may further contain one or more additional ingredients, including, but not limited to, suspending agents, stabilizers, or dispersing agents. Formulations may also include aqueous solutions, which may contain excipients such as salts, carbohydrates, and buffers, or sterile, pyrogen-free water. Exemplary dosage forms may include solutions or suspensions in sterile aqueous solutions, such as aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered, if desired.

[0142] The compositions of the present invention may further contain other auxiliary ingredients conventionally found in pharmaceutical compositions.Thus, for example, the compositions may contain additional compatible pharmaceutically active materials, such as antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, preservatives, antioxidants, opacifiers, thickeners and stabilizers.However, when added, such materials should not excessively interfere with the biological activity of the components of the compositions of the present disclosure.The preparations may be sterilized, and if desired, may be mixed with auxiliary agents that do not adversely interact with the preparation, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for affecting osmotic pressure, buffers, coloring agents and / or aromatic substances.

[0143] In some embodiments, one or more pharmaceutically active ingredients may be used in combination with the engineered B cells.

[0144] In some embodiments, the transfected and activated B cells using the methods described herein or other methods known in the art are administered to the patient in conjunction with (e.g., before, simultaneously with, or after) any number of appropriate treatment modalities, including, but not limited to, treatment with drugs such as antivirals, chemotherapy, radiation, immunosuppressants such as cyclosporine, bisulfin, bortezomib, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation. These drugs either inhibit the calcium-dependent phosphatase calcineurin (cyclosporine and FK506), inhibit the proteasome (bortezomib), or inhibit p70S6 kinase (rapamycin), which is important for growth factor-induced signal transduction (Liu et al, Cell 66:807-815, 1991; Henderson et al, Immun. 73:316-321, 1991; Bierer et al, Curr. Opin. Immun. 5:763-773, 1993; Isoniemi (supra)).

[0145] The dosage of the composition administered to a patient will vary depending on the condition being treated and the exact nature of the recipient of the treatment. Scaling of dosages for human administration can be performed according to generally accepted practices in the art.

[0146] In some embodiments, the cell composition is assessed for purity prior to administration. In some embodiments, the cell composition is tested for robustness of therapeutic agent production. In some embodiments, the cell composition is tested for sterility. In some embodiments, the cell composition is screened to ensure it is a match for the recipient subject.

[0147] In some embodiments, the cell composition is stored and / or shipped at 4°C. In another embodiment, the cell composition is frozen for storage and / or shipping. The cell composition may be frozen at, for example, -20°C or -80°C. In some embodiments, the step of freezing the cell composition comprises liquid nitrogen. In one embodiment, the cell composition is frozen using a controlled rate freezer. Thus, the methods described herein may further comprise a thawing step. Engineered B cells

[0148] In certain embodiments of the methods described herein, B cells can be obtained from a unit of blood collected from a subject using several techniques known to those skilled in the art, such as FICOLL™ (a copolymer of sucrose and epichlorohydrin that can be used to prepare high-density solutions) separation. B cells can be obtained from several sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, tissue from a site of infection, spleen tissue, and tumors. In some embodiments, cells from an individual's circulating blood are obtained by apheresis or leukapheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In some embodiments, cells collected by apheresis can be washed to remove the plasma fraction and to place the cells in an appropriate buffer or medium for subsequent processing steps. In one embodiment of the methods described herein, the cells are washed with phosphate-buffered saline (PBS). In alternative embodiments, the wash solution lacks calcium, may lack magnesium, or may lack many, if not all, divalent cations. As those skilled in the art will readily appreciate, the washing step can be accomplished by methods known to those skilled in the art, for example, by using a semi-automated "flow-through" centrifuge (e.g., a Cobe 2991 cell processor) according to the manufacturer's instructions. After washing, the cells can be resuspended in various biocompatible buffers, such as PBS. Alternatively, undesirable components of the apheresis sample can be removed and the cells resuspended directly in culture medium.

[0149] B cells can be isolated from peripheral blood or leukapheresis using techniques known in the art. For example, PBMCs can be isolated using FICOLL™ (Sigma-Aldrich, St. Louis, MO), and CD19+ B cells can be purified by negative or positive selection using any of a variety of antibodies known in the art, such as the Rosette tetrameric complex system (StemCell Technologies, Vancouver, Canada) or MACS™ MicroBead Technology (Miltenyi Biotec, San Diego, CA). In some embodiments, memory B cells are isolated as described in Jourdan et al. (Blood. 2009 Dec 10; 114(25):5173-81). For example, after depletion of CD2+ cells using anti-CD2 magnetic beads, CD19+CD27+ memory B cells can be sorted by FACS. Bone marrow plasma cells (BMPCs) can be purified using anti-CD138 magnetic microbead sorting or other similar methods and reagents. Human B cells can be isolated, for example, using CD19 MicroBeads, human (Miltenyi Biotec, San Diego, CA). Human memory B cells can be isolated, for example, using the Memory B Cell Isolation Kit, human (Miltenyi Biotec, San Diego, CA).

[0150] Other isolation kits are commercially available, such as R&D Systems' MagCellect Human B Cell Isolation Kit (Minneapolis, MN). In some embodiments, resting B cells can be prepared by sedimentation on a discontinuous Percoll gradient, as described in (Defranco et al., (1982) J. Exp. Med. 155: 1523).

[0151] In some embodiments, peripheral blood mononuclear cells (PBMCs) are obtained from a blood sample using gradient-based purification (e.g., FICOLL™). In some embodiments, PBMCs are obtained from an apheresis-based collection. In one embodiment, B cells are isolated from PBMCs by isolating pan-B cells. The isolating step may utilize positive and / or negative selection. In some embodiments, negative selection comprises depleting T cells using anti-CD3-conjugated microbeads, thereby providing a T-cell-depleted fraction. In some embodiments, memory B cells are isolated from the pan-B cell or T-cell-depleted fraction by positive selection for CD27. In one particular embodiment, memory B cells are isolated by depletion of unwanted cells and subsequent positive selection using CD27 MicroBeads. Unwanted cells, such as T cells, NK cells, monocytes, dendritic cells, granulocytes, platelets and red blood cells, can be depleted using a cocktail of biotinylated antibodies against CD2, CD14, CD16, CD36, CD43 and CD235a (glycophorin A) and Anti-Biotin MicroBeads.

[0152] In some embodiments, switched memory B cells are obtained. "Switched memory B cells" or "switched B cells," as used herein, refer to B cells that have undergone isotype class switching. In some embodiments, switched memory B cells are positively selected for IgG. In some embodiments, switched memory B cells are obtained by depleting IgD- and IgM-expressing cells. Switched memory B cells can be isolated, for example, using the Switched Memory B Cell Kit, human (Miltenyi Biotec, San Diego, CA).

[0153] For example, in some embodiments, non-target cells can be labeled with a cocktail of biotinylated CD2, CD14, CD16, CD36, CD43, CD235a (glycophorin A), anti-IgM, and anti-IgD antibodies. These cells can be subsequently magnetically labeled with Anti-Biotin MicroBeads. Highly pure switched memory B cells can be obtained by depletion of the magnetically labeled cells.

[0154] In some embodiments, a promoter sequence from a gene unique to memory B cells, such as the CD27 gene (or other gene specific to memory B cells and not expressed in naive B cells), is used to drive expression of a selectable marker, such as a mutated dihydrofolate reductase gene, that allows for positive selection of memory B cells in the presence of methotrexate. In another embodiment, a promoter sequence from a pan-B cell gene, such as the CD19 gene, is used to drive expression of a selectable marker, such as a mutated dihydrofolate reductase gene, that allows for positive selection of memory B cells in the presence of methotrexate. In another embodiment, T cells are depleted using CD3 or by the addition of cyclosporine. In some embodiments, CD138+ cells are isolated from pan-B cells by positive selection. In some embodiments, CD138+ cells are isolated from PBMCs by positive selection. In some embodiments, CD38+ cells are isolated from pan-B cells by positive selection. In some embodiments, CD38+ cells are isolated from PBMCs by positive selection. In some embodiments, CD27+ cells are isolated from PBMCs by positive selection. In some embodiments, memory B cells and / or plasma cells are selectively expanded from PBMCs using in vitro culture methods available in the art.

[0155] In some embodiments, the genetically modified B cells are autologous to the subject. In some embodiments, the genetically modified B cells are allogeneic to the subject.

[0156] B cells, e.g., memory B cells, can be cultured using in vitro methods that activate B cells and differentiate them into plasma cells, plasmablasts, or both. As will be appreciated by those skilled in the art, plasma cells can be identified by cell surface protein expression patterns using standard flow cytometry methods. For example, terminally differentiated plasma cells express relatively few surface antigens and do not express common pan-B cell markers, e.g., CD19 and CD20. Instead, plasma cells can be identified by the expression of CD38, CD78, CD138, and IL-6R, and the lack of CD45 expression. CD27 can also be used to identify plasma cells, since naive B cells are CD27-, memory B cells are CD27+, and plasma cells are CD27++. Plasma cells express high levels of CD38 and CD138.

[0157] In some embodiments, the genetically modified B cells are CD20-, CD38+, and CD138+. In some embodiments, the genetically modified B cells are CD20-, CD38+, and CD138-.

[0158] As used herein, unless otherwise specified with respect to a viral vector, "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. Exemplary vectors include plasmids, minicircles, transposons (e.g., Sleeping Beauty transposons), yeast artificial chromosomes, self-replicating RNA, and viral genomes. While certain vectors can replicate autonomously in host cells, other vectors can be integrated into the genome of the host cell, thereby replicating along with the host genome. Furthermore, certain vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"), which contain nucleic acid sequences operably linked to expression control sequences and are thus capable of directing the expression of those sequences. In certain embodiments, the expression construct is derived from a plasmid vector. Exemplary constructs include modified pNASS vectors (Clontech, Palo Alto, CA) containing nucleic acid sequences encoding ampicillin resistance genes, polyadenylation signals, and T7 promoter sites; pDEF38 and pNEF38 (CMC ICOS Biologies, Inc.) containing the CHEF1 promoter; and pD18 (Lonza) containing the CMV promoter. Other suitable mammalian expression vectors are well known (see, e.g., Ausubel et al., 1995; Sambrook et al., supra; see also, e.g., catalogs from Invitrogen, San Diego, CA; Novagen, Madison, WI; Pharmacia, Piscataway, NJ).

[0159] Useful constructs can be prepared that contain a dihydrofolate reductase (DHFR) coding sequence under appropriate regulatory control to facilitate enhanced production levels of the fusion protein, which results from gene amplification after application of an appropriate selection agent (e.g., methotrexate). In one embodiment, the use of a bifunctional transposon encoding a therapeutic gene (e.g., IDUA) with a drug-resistant DHFR gene, combined with incubation in methotrexate (MTX) to enrich for successfully translocated B cells, generates a more potent product.

[0160] Generally, recombinant expression vectors contain an origin of replication, a selectable marker that allows transformation of host cells, and a promoter derived from a highly expressed gene that directs transcription of downstream structural sequences, as described above. A vector operably linked to a polynucleotide according to the present disclosure results in a cloning or expression construct. Exemplary cloning / expression constructs contain at least one expression control element, such as a promoter, operably linked to a polynucleotide of the present disclosure. Additional expression control elements, such as enhancers, factor-specific binding sites, terminators, and ribosome binding sites, are also contemplated in vectors and cloning / expression constructs according to the present disclosure. The heterologous structural sequence of a polynucleotide according to the present disclosure is assembled in appropriate phase with translation initiation and termination sequences. Thus, for example, the encoding nucleic acids provided herein can be included in any one of a variety of expression vector constructs (e.g., minicircles) as recombinant expression constructs for expressing such proteins in host cells.

[0161] Suitable DNA sequence(s) can be inserted into a vector, for example, by various procedures. Generally, the DNA sequence is inserted into suitable restriction endonuclease cleavage site(s) by procedures known in the art. Standard techniques for cloning, DNA isolation, amplification and purification, as well as various separation techniques for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonuclease, etc., are contemplated. Some standard techniques are described, for example, in Ausubel et al. (Current Protocols in Molecular Biology, Greene Publ. Assoc. Inc. & John Wiley & Sons, Inc., Boston, MA, 1993); Sambrook et al. (Molecular Cloning, Second Ed., Cold Spring Harbor Laboratory, Plainview, NY, 1989); Maniatis et al. (Molecular Cloning, Cold Spring Harbor Laboratory, Plainview, NY, 1982); Glover (Ed.) (DNA Cloning Vol. I and II, IRL Press, Oxford, UK, 1985); Hames and Higgins (Eds.) (Nucleic Acid Hybridization, IRL Press, Oxford, UK, 1985); and elsewhere.

[0162] The DNA sequence in the expression vector is operably linked to at least one appropriate expression control sequence (e.g., a constitutive promoter or a regulated promoter) to direct mRNA synthesis. Representative examples of such expression control sequences include promoters of eukaryotic cells or their viruses, as described above. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors, kanamycin vectors, or other vectors with selectable markers. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retroviruses, EEK, EF1 alpha, and mouse metallothionein-1. Selection of appropriate vectors and promoters is well within the level of ordinary skill in the art; the preparation of certain particularly preferred recombinant expression constructs comprising at least one promoter or regulated promoter operably linked to a nucleic acid encoding a protein or polypeptide in accordance with the present disclosure is described herein.

[0163] In some embodiments, the plasmid may comprise the sequence of SEQ ID NO: 1. In some embodiments, the plasmid may consist of the sequence of SEQ ID NO: 1. In some embodiments, the plasmid may comprise or consist of a sequence that is at least about 60% identical to SEQ ID NO: 1. In some embodiments, the plasmid may comprise or consist of a sequence that is at least about 85% identical to SEQ ID NO: 1, or at least about 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% identical to SEQ ID NO: 1.

[0164] Variants of the polynucleotides of the present disclosure are also contemplated. Variant polynucleotides are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical to one of the polynucleotides of the specified sequence, as described herein, or hybridize to one of the polynucleotides of the specified sequence under stringent hybridization conditions of 0.015 M sodium chloride, 0.0015 M sodium citrate at about 65-68°C, or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at about 42°C. Polynucleotide variants retain the ability to encode a functional binding domain or fusion protein thereof as described herein.

[0165] In some embodiments, genetically modified B cells are transfected with a transgene. Exemplary methods for transfecting B cells are provided in WO2014 / 152832 and WO2016 / 100932, both of which are incorporated herein by reference in their entirety. B cell transfection can be achieved using any of a variety of methods available in the art for introducing DNA or RNA into B cells. Suitable techniques can include calcium phosphate transfection, DEAE-dextran, electroporation, pressure-mediated transfection or "cell squeezing" (e.g., CellSqueeze microfluidic system, SQZ Biotechnologies), nanoparticle-mediated or liposome-mediated transfection, and transduction using retroviruses or other viruses, such as vaccinia. See, for example, Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratories; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al., 1981, Gene 13:197; US 5,124,259; US 5,297,983; US 5,283,185; US 5,661,018; US 6,878,548; US 7,799,555; US 8,551,780; and US 8,633,029. An example of a commercially available electroporation technique suitable for B cells is Nucleofector™ transfection technology. Transfection may be carried out before or during the in vitro culture of the isolated B cells in the presence of one or more of the activation and / or differentiation factors described above.For example, cells are transfected on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 of in vitro culture. In some embodiments, cells are transfected on day 1, 2, or 3 of in vitro culture. In some embodiments, cells are transfected on day 2 of in vitro culture. For example, cells are electroporated on day 2 of in vitro culture, e.g., for delivery of a plasmid, transposon, minicircle, or self-replicating RNA. In another embodiment, cells are transfected on day 4, 5, 6, or 7 of in vitro culture. In some embodiments, cells are transfected on day 6 of in vitro culture. In another embodiment, the cells are transfected on day 5 of in vitro culture.

[0166] In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) prior to activation. In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) during activation. In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) after activation. In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) prior to differentiation. In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) during differentiation. In some embodiments, cells are transfected or otherwise manipulated (e.g., via targeted integration of a transgene) after differentiation.

[0167] In some embodiments, non-viral vectors are used to deliver DNA or RNA to memory B cells and / or plasma cells.For example, the system that can facilitate the transfection of memory B cells and / or plasma cells without the need for viral integration system includes but is not limited to transposon (for example, Sleeping Beauty transposon system), zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), clustered regularly interspaced short palindromic repeats (CRISPR), meganuclease, minicircle, replicon, artificial chromosome (for example, bacterial artificial chromosome, mammalian artificial chromosome and yeast artificial chromosome), plasmid, cosmid and bacteriophage.

[0168] In some embodiments, the genetically modified B cells are prepared using a Sleeping Beauty transposon to express a therapeutic agent in the B cells. In some embodiments, the genetically modified B cells are prepared using a recombinant viral vector to express a therapeutic agent in the B cells. In some embodiments, the recombinant viral vector encodes a recombinant retrovirus, a recombinant lentivirus, a recombinant adenovirus, or a recombinant adeno-associated virus.

[0169] In some embodiments, such non-viral vector systems can also be delivered via viral vectors known in the art or described below.For example, in some embodiments, viral vectors (e.g., retroviruses, lentiviruses, adenoviruses, adeno-associated viruses) are used to deliver one or more non-viral vectors (e.g., one or more of the above-mentioned zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeats (CRISPRs), meganucleases, etc.), or any other enzymes / complementary vectors, polynucleotides and / or polypeptides that can facilitate targeted integration.Therefore, in some embodiments, cells (e.g., B cells, e.g., memory B cells and / or plasma cells) can be engineered to express exogenous sequences (e.g., sequences encoding therapeutic polypeptides, e.g., IDUA) via targeted integration methods. Such methods are known in the art and may include cleaving an endogenous locus in a cell using one or more nucleases (e.g., ZFN, TALEN, CRISPR / Cas, meganuclease), and administering a transgene to the cell so that the transgene is integrated into the endogenous locus and expressed in the cell. The transgene may be included in a donor sequence that is integrated into the DNA of the host cell at or near the point of cleavage by the nuclease. In some embodiments, genetically modified B cells are prepared by gene editing of the genome of the B cell or by targeted integration of a polynucleotide sequence encoding a therapeutic agent into the genome of the B cell.

[0170] In some embodiments, targeted integration comprises zinc finger nuclease-mediated gene integration, CRISPR-mediated gene integration or gene editing, TALE-nuclease-mediated gene integration, or meganuclease-mediated gene integration.In some embodiments, targeted integration of polynucleotide is carried out by homologous recombination.In some embodiments, targeted integration comprises viral vector-mediated delivery of the nuclease that can induce DNA cleavage at target site.In some embodiments, the nuclease is zinc finger nuclease, Cas nuclease, TALE-nuclease, or meganuclease.

[0171] Integration of an exogenous sequence (e.g., a sequence encoding a therapeutic polypeptide, e.g., IDUA) can occur via recombination. As will be apparent to those skilled in the art, "recombination" refers to the process of exchanging genetic information between two polynucleotides, including, but not limited to, non-homologous end joining (NHEJ) and donor capture by homologous recombination. The recombination can be homologous recombination. For purposes of this disclosure, "homologous recombination (HR)" refers to a specialized form of such exchange that occurs, for example, during repair of a double-strand break in a cell via a homology-directed repair mechanism. This process utilizes nucleotide sequence homology, whereby a "donor" molecule (e.g., a donor polynucleotide sequence, or a donor vector containing such a sequence) is used by the cell's DNA repair machinery as a template for repair of a "target" molecule (i.e., a molecule that has experienced a double-strand break), and these mechanisms result in the transfer of genetic information from the donor to the target. In some embodiments of HR-directed integration, the donor molecule can contain at least two regions of homology to the genome ("homology arms"). In some embodiments, the homology arms can be, for example, at least 50-100 base pairs in length. The homology arms can have substantial DNA homology to a region of genomic DNA adjacent to the cleavage site where targeted integration occurs. The homology arms of the donor molecule can flank the DNA to be integrated into the target genome or target DNA locus. Chromosomal cleavage and subsequent repair using the homologous region of the plasmid DNA as a template can result in the transfer of the intervening transgene, flanked by the homology arms, into the genome. See, e.g., Roller et al. (1989) Proc. Natl. Acad Sci. USA. 86(22): 8927-8931; Thomas et al. (1986) Cell 44(3):419-428.The frequency of this type of homology-directed targeted integration can be increased by up to 105-fold by intentionally creating a double-strand break near the target region (Hockemeyer et al. (2009) Nature Biotech. 27(9):851-857; Lombardo et al. (2007) Nature Biotech. 25(11): 1298-1306; Moehle et al. (2007) Proc. Natl. Acad. Sci. USA 104(9):3055-3060; Rouet et al. (1994) Proc. Natl. Acad. Sci. USA 91 (13):6064-6068).

[0172] Any nuclease capable of mediating targeted cleavage of a genomic locus so that a transgene can be integrated into the genome of a target cell (e.g., by recombination such as HR) can be utilized in engineering cells (e.g., memory B cells or plasmablasts) in accordance with the present disclosure.

[0173] Double-strand breaks (DSBs) or nicks can be created by site-specific nucleases, such as zinc finger nucleases (ZFNs), TAL effector domain nucleases (TALENs), meganucleases, or by using CRISPR-mediated systems with engineered crRNA / tract RNA (single guide RNA) to guide specific cleavage. See, for example, Burgess (2013) Nature Reviews Genetics 14:80-81, Umov et al. (2010) Nature 435(7042):646-51; U.S. Patent Application Publication Nos. 2003 / 0232410; 2005 / 0208489; 2005 / 0026157, 2005 / 0064474; 2006 / 0188987, 2009 / 0263900; 2009 / 0117617; 2010 / 0047805; 2011 / 0207221; 2011 / 0301073 and International Patent Application Publication No. WO2007 / 014275, the disclosures of which are incorporated herein by reference in their entireties for all purposes.

[0174] In some embodiments, cells (e.g., memory B cells or plasmablasts) are engineered through zinc finger nuclease-mediated targeted integration of a donor construct. Zinc finger nucleases (ZFNs) are enzymes that can recognize and cleave target nucleotide sequences with specificity due to the coupling of a "zinc finger DNA-binding protein" (ZFP) (or binding domain), which binds DNA in a sequence-specific manner via one or more zinc fingers, with a nuclease enzyme. ZFNs can include any suitable cleavage domain (e.g., a nuclease enzyme) operably linked to a ZFP DNA-binding domain to form engineered ZFNs that can facilitate site-specific cleavage of target DNA sequences (see, e.g., Kim et al. (1996) Proc Natl Acad Sci USA 93(3): 1156-1160). For example, ZFNs can include a target-specific ZFP linked to a portion of the FORI enzyme or FOK1 enzyme. In some embodiments, the ZFN used in ZFN-mediated targeted integration approach utilizes two separate molecules, each of which comprises a subunit of FOK1 enzyme bound to a ZFP, each ZFP having specificity for the DNA sequence adjacent to the target cleavage site, and when the two ZFPs bind to their respective target DNA sites, the FOK1 enzyme subunits come into proximity with each other and bind together to activate the nuclease activity of cleaving the target cleavage site.ZFN has been used for genome modification in various organisms (for example, U.S. Patent Application Publication No. 20030232410; U.S. Patent Application Publication No. 20050208489; U.S. Patent Application Publication No. 20050026157; U.S. Patent Application Publication No. 20050064474; U.S. Patent Application Publication No. 20060188987; U.S. Patent Application Publication No. 20060063231; and International Publication No. WO07 / 014,275, which are incorporated herein by reference in their entirety). Custom ZFPs and ZFNs are commercially available, for example, from Sigma Aldrich (St. Louis, MO), and any location in DNA can be routinely targeted and cleaved using such custom ZFNs.

[0175] In some embodiments, cells (e.g., memory B cells or plasmablasts) are engineered via CRISPR-mediated (e.g., CRISPR / Cas) nuclease-mediated integration of a donor construct. The CRISPR (clustered regularly interspaced short palindromic repeats) / Cas (CRISPR-associated) nuclease system is a bacterial-based engineered nuclease system that can be used for genome engineering. It is based in part on the adaptive immune response of many bacteria and archaea. When a virus or plasmid invades bacteria, a segment of the invader's DNA is converted into CRISPR RNA (crRNA) by the "immune" response. This crRNA then associates with another type of RNA, called tracrRNA, through a region of partial complementarity, guiding the Cas (e.g., Cas9) nuclease to a region in the target DNA that is homologous to the crRNA, called the "protospacer." Cas cleaves the DNA to generate blunt ends at DSBs at sites specified by a 20-nucleotide guide sequence contained within the crRNA transcript. Cas requires both crRNA and tracrRNA for site-specific DNA recognition and cleavage. This system has now been engineered so that crRNA and tracrRNA can be combined into one molecule ("single-guide RNA"), and the crRNA portion of the single-guide RNA can be engineered to guide Cas nuclease to target any desired sequence (see Jinek et al (2012) Science 337, pp. 816-821; Jinek et al, (2013), eLife 2:e00471; and David Segal, (2013) eLife 2:e00563). Thus, the CRISPR / Cas system can be engineered to create DSBs at desired targets in the genome, and repair of the DSBs can be affected by the use of repair inhibitors to increase error-prone repair. In some embodiments, CRISPR / Cas nuclease-mediated integration utilizes type II CRISPR. Type II CRISPR is one of the most well-characterized systems and carries out targeted DNA double-strand breaks in four sequential steps.First, two non-coding RNAs, the pre-crRNA and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the repeat region of the pre-crRNA and mediates processing of the pre-crRNA into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas to the target DNA through Watson-Crick base pairing between the spacer on the crRNA and the protospacer on the target DNA adjacent to the protospacer adjacent motif (PAM), an additional requirement for target recognition. Fourth, Cas mediates cleavage of the target DNA, creating a double-strand break within the protospacer.

[0176] The Cas-associated CRISPR / Cas system comprises two non-coding RNA components: a tracrRNA and a pre-crRNA array containing nuclease guide sequences (spacers) spaced by identical direct repeats (DRs). To use the CRISPR / Cas system to achieve genome engineering, both of these RNA functions must be present (see Cong et al., (2013) Sciencexpress 1 / 10.1126 / science 1231143). In some embodiments, the tracrRNA and pre-crRNA are provided via separate expression constructs or as separate RNAs. In other embodiments, chimeric RNAs are constructed in which an engineered mature crRNA (which confers target specificity) is fused to the tracrRNA (which provides interaction with Cas) to create chimeric cr-RNA-tracrRNA hybrids (also called single-guide RNAs). (See Jinek, ibid. and Cong, ibid.).

[0177] In some embodiments, a single guide RNA containing both crRNA and tracrRNA can be engineered to guide Cas nuclease to target any desired sequence (e.g., Jinek et al (2012) Science 337, p. 816-821; Jinek et al, (2013), eLife 2:e00471; David Segal, (2013) eLife 2:e00563). Thus, the CRISPR / Cas system can be engineered to create DSBs at desired targets in the genome.

[0178] Custom CRISPR / Cas systems are commercially available, for example, from Dharmacon (Lafayette, CO), and any location in DNA can be routinely targeted and cleaved using such custom single-guide RNA sequences. Single-stranded DNA templates for recombination can be synthesized (e.g., via art-known and commercially available oligonucleotide synthesis methods) or provided in a vector, e.g., a viral vector, e.g., AAV. In some embodiments, cells (e.g., memory B cells or plasmablasts) are engineered via TALE-nuclease (TALEN)-mediated targeted integration of a donor construct. A "TALE DNA-binding domain" or "TALE" is a polypeptide containing one or more TALE repeat domains / units. The repeat domain is responsible for binding of the TALE to its cognate target DNA sequence. A single "repeat unit" (also referred to as a "repeat") is typically 33-35 amino acids in length and exhibits at least some sequence homology to other TALE repeat sequences within naturally occurring TALE proteins. TAL effectors can contain a nuclear localization sequence, an acidic transcriptional activation domain, and a cluster of tandem repeats, each containing approximately 34 amino acids that are important for the DNA-binding specificity of these proteins (e.g., Schornack S, et al (2006) J Plant Physiol 163(3): 256-272). TAL effectors rely on sequences found in tandem repeats, which contain approximately 102 bp, and the repeats are typically 91-100% homologous to each other (e.g., Bonas et al (1989) Mol Gen Genet 218: 127-136). These DNA-binding repeats can be engineered into proteins with new combinations and repeat numbers to create artificial transcription factors that can interact with new sequences and activate the expression of non-endogenous reporter genes (e.g., Bonas et al (1989) Mol Gen Genet 218: 127-136).Engineered TAL proteins can be linked to Fokl cleavage half-domains to obtain TAL effector domain nuclease fusions (TALENs) that cleave target-specific DNA sequences (e.g., Christian et al (2010) Genetics epub 10.1534 / genetics.l l0.120717).

[0179] Custom TALENs are commercially available, for example, from Thermo Fisher Scientific (Waltham, Mass.), and any location in DNA can be routinely targeted and cleaved.

[0180] In some embodiments, cells (e.g., memory B cells or plasmablasts) are engineered via meganuclease-mediated targeted integration of a donor construct. Meganucleases (or "homing endonucleases") are endonucleases that bind and cleave double-stranded DNA at recognition sequences larger than 12 base pairs. Naturally occurring meganucleases can be monomelic (e.g., I-Scel) or dimeric (e.g., I-Crel). Naturally occurring meganucleases recognize cleavage sites of 15-40 base pairs and are generally grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family, and the HNH family. Exemplary homing endonucleases include I-Scel, I-Ceul, PI-PspI, PI-Sce, I-SceIV, I-Csml, I-Panl, I-Scell, I-Ppol, I-SceIII, I-Crel, I-Tevl, I-TevII, and I-TevIII, whose recognition sequences are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al. (1989) Gene 82: 115-118; Perler et al. (1994) Nucleic Acids Res. 22, 1125-1127; Jasin (1996) Trends Genet. 12:224-228; Gimble et al. (1996) J. Mol. Biol. 263: 163-180; Argast et al. (1998) J. Mol. Biol. 280:345-353 and the New England Biolabs catalog. The term "meganuclease" includes monomeric meganucleases, dimeric meganucleases, and monomers that associate to form dimeric meganucleases.

[0181] In some embodiments, the methods and compositions described herein use nucleases, including engineered (non-naturally occurring) homing endonucleases (meganucleases). Recognition sequences for homing endonucleases and meganucleases, such as I-Scel, I-Ceul, PI-PspI, PI-Sce, I-SceIV, I-Csml, I-Panl, I-SceII, I-Ppol, I-SceIII, I-Crel, I-Tevl, I-TevII, and I-TevIII, are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al. (1989) Gene 82: 115-118; Perler et al. (1994) Nucleic Acids Res. 22, 1125-1127; Jasin (1996) Trends Genet. 12:224-228; Gimble et al. (1996) J. Mol. Biol. 263: 163-180; Argast et al. (1998) J. Mol. Biol. 280:345-353 and the New England Biolabs catalog. Furthermore, the DNA binding specificity of homing endonucleases and meganucleases can be engineered to bind non-natural target sites. See, for example, Chevalier et al. (2002) Molec. Cell 10:895-905; Epinat et al. (2003) Nucleic Acids Res. 31:2952-2962; Ashworth et al. (2006) Nature 441:656-659; Paques et al. (2007) Current Gene Therapy 7:49-66; U.S. Patent Application Publication No. 20070117128. The DNA binding domain of homing endonucleases and meganucleases can be altered as a whole (i.e., so that the nuclease contains a cognate cleavage domain) or fused to a heterologous cleavage domain.Custom meganucleases are commercially available, for example, from New England Biolabs (Ipswich, Mass.), and any location in DNA can be routinely targeted and cleaved.

[0182] Engineering B cells can include administering one or more nucleases (e.g., ZFN, TALEN, CRISPR / Cas, meganucleases) to the B cells, e.g., via one or more vectors encoding the nucleases, such that the vectors containing the encoded nucleases are taken up by the B cells. The vectors can be viral vectors.

[0183] In some embodiments, a nuclease cleaves a specific endogenous locus (e.g., a safe harbor gene or a locus of interest) in a cell (e.g., a memory B cell or a plasma cell), and one or more exogenous (donor) sequences (e.g., a transgene) (e.g., one or more vectors containing these exogenous sequences) are administered. The nuclease may induce a double-strand break (DSB) or a single-strand break (nick) in the target DNA. In some embodiments, targeted insertion of the donor transgene may be performed via homology-directed repair (HDR), non-homologous repair mechanisms (e.g., NHEJ-mediated end capture), or insertion and / or deletion of nucleotides (e.g., endogenous sequences) at the site of integration of the transgene into the genome of the cell.

[0184] In some embodiments, the method of transfecting B cells comprises electroporating the B cells prior to contacting the B cells with the vector. In some embodiments, the cells are electroporated on day 1, 2, 3, 4, 5, 6, 7, 8, or 9 of in vitro culture. In some embodiments, the cells are electroporated on day 2 of in vitro culture for plasmid delivery. In some embodiments, the cells are transfected using a transposon on day 1, 2, 3, 4, 5, 6, 7, 8, or 9 of in vitro culture. In some embodiments, the cells are transfected using a minicircle on day 1, 2, 3, 4, 5, 6, 7, 8, or 9 of in vitro culture. In some embodiments, electroporation of the Sleeping Beauty transposon is performed on day 2 of in vitro culture.

[0185] In some embodiments, B cells are contacted with a vector comprising a nucleic acid of interest operably linked to a promoter under conditions sufficient to transfect at least a portion of the B cells. In some embodiments, B cells are contacted with a vector comprising a nucleic acid of interest operably linked to a promoter under conditions sufficient to transfect at least 5% of the B cells. In some embodiments, B cells are contacted with a vector under conditions sufficient to transfect at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or even 100% of the B cells. In some embodiments, B cells cultured in vitro as described herein are transfected, where the cultured B cells are contacted with a vector described herein under conditions sufficient to transfect at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or even 100% of the B cells.

[0186] Viral vectors can be used to transduce memory B cells and / or plasma cells. Examples of viral vectors include, but are not limited to, adenovirus-based vectors, adeno-associated virus (AAV)-based vectors, retrovirus vectors, retrovirus-adenovirus vectors, and vectors derived from herpes simplex virus (HSV), including amplicon vectors, replication-deficient HSV, and attenuated HSV (see, for example, Krisky, Gene Ther. 5: 1517-30, 1998; Pfeifer, Annu. Rev. Genomics Hum. Genet. 2: 177-211, 2001, each of which is incorporated by reference in its entirety). In some embodiments, cells are transduced with a viral vector (e.g., a lentiviral vector) on day 1, 2, 3, 4, 5, 6, 7, 8, or 9 of in vitro culture. In some embodiments, cells are transduced with a viral vector on day 5 of in vitro culture. In some embodiments, the viral vector is a lentivirus. In some embodiments, the cells are transduced with a measles virus-pseudotyped lentivirus on day 1 of in vitro culture.

[0187] In some embodiments, B cells are transduced with a retroviral vector using any of a variety of techniques known in the art (see, e.g., Science 12 April 1996 272: 263-267; Blood 2007, 99:2342-2350; Blood 2009, 1 13: 1422-1431; Blood 2009 Oct 8; 1 14(15):3173-80; Blood. 2003;101 (6):2167-2174; Current Protocols in Molecular Biology or Current Protocols in Immunology, John Wiley & Sons, New York, NY (2009)). Additional descriptions of viral transduction of B cells can be found in WO2011 / 085247 and WO2014 / 152832, each of which is incorporated by reference herein in its entirety.

[0188] For example, donor-derived PBMCs, B or T lymphocytes, and other B-cell cancer cells, e.g., B-CLL, can be isolated and cultured in IMDM medium or RPMI 1640 (GibcoBRL Invitrogen, Auckland, New Zealand) as described herein or other suitable medium, either serum-free or supplemented with serum (e.g., 5-10% FCS, human AB serum, and serum substitutes), penicillin / streptomycin, and / or other suitable supplements, e.g., transferrin and / or insulin. In some embodiments, cells are cultured at 1 x 10 in a 48-well plate. 5 The cells are seeded, and the concentrated vector is added at various doses, which can be routinely optimized by those skilled in the art using conventional methodology.In one embodiment, B cells are transferred to MS5 cell monolayer in RPMI supplemented with 10% AB serum, 5% FCS, 50ng / ml rhSCF, 10ng / ml rhlL-15 and 5ng / ml rhlL-2, and the medium is periodically refreshed as needed.As will be appreciated by those skilled in the art, other suitable medium and supplements can be used as desired.

[0189] Some embodiments relate to the use of retroviral vectors or vectors derived from retroviruses. "Retroviruses" are enveloped RNA viruses that can infect animal cells and utilize the enzyme reverse transcriptase in the early stages of infection to generate DNA copies from their RNA genomes, which are then typically integrated into the host genome. Examples of retroviral vectors include Moloney murine leukemia virus (MLV)-derived vectors, murine stem cell virus-based retroviral vectors (see, for example, Hawley et al., PNAS USA 93: 10297-10302, 1996; Keller et al., Blood 92: 877-887, 1998), which provide long-term stable expression in target cells, such as hematopoietic progenitor cells and their differentiated progeny, hybrid vectors (see, for example, Choi, et al., Stem Cells 19: 236-246, 2001), and complex retrovirus-derived vectors, such as lentiviral vectors.

[0190] In some embodiments, B cells are contacted with a retroviral vector comprising a nucleic acid of interest operably linked to a promoter under conditions sufficient to transduce at least a portion of the B cells. In one embodiment, B cells are contacted with a retroviral vector comprising a nucleic acid of interest operably linked to a promoter under conditions sufficient to transduce at least 2% of the B cells. In some embodiments, B cells are contacted with the vector under conditions sufficient to transduce at least 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or even 100% of resting B cells. In some embodiments, differentiated and activated B cells cultured in vitro as described herein are transduced, where the cultured differentiated / activated B cells are contacted with a vector described herein under conditions sufficient to transduce at least 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or even 100% of the differentiated and activated B cells.

[0191] In some embodiments, prior to transduction, cells are pre-stimulated with Staphylococcus Aureus Cowan (SAC; Calbiochem, San Diego, CA) and / or IL-2 at appropriate concentrations known to those of skill in the art and routinely optimized. Other B cell activators (e.g., PMA) known to those of skill in the art and described herein may be used.

[0192] As mentioned above, some embodiments use lentiviral vectors. The term "lentivirus" refers to a genus of complex retroviruses that can infect both dividing and non-dividing cells. Examples of lentiviruses include HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2), visna maedi, caprine arthritis-encephalitis virus, equine infectious anemia virus, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), and simian immunodeficiency virus (SIV). Lentiviral vectors can be derived from any one or more of these lentiviruses (see, e.g., Evans et al, Hum Gene Ther. 10: 1479-1489, 1999; Case et al, PNAS USA 96:2988-2993, 1999; Uchida et al, PNAS USA 95: 1 1939-1 1944, 1998; Miyoshi et al, Science 283:682-686, 1999; Sutton et al, J Virol 72:5781 -5788, 1998; and Frecha et al, Blood. 1 12:4843-52, 2008, each of which is incorporated by reference in its entirety).

[0193] It has been demonstrated that resting T and B cells can be transduced by VSVG-coated LVs that retain most of the HIV accessory proteins (vif, vpr, vpu, and nef) (see, e.g., Frecha et al., 2010 Mol. Therapy 18: 1748). In certain embodiments, the retroviral vector comprises a specific minimal sequence derived from a lentiviral genome, such as an HIV or SIV genome. The lentiviral genome typically consists of a 5' long terminal repeat (LTR) region, a gag gene, a pol gene, an env gene, accessory genes (e.g., nef, vif, vpr, vpu, tat, rev), and a 3' LTR region. The viral LTR is divided into three regions, designated U3, R (repeat), and U5. The U3 region contains enhancer and promoter elements, the U5 region contains a polyadenylation signal, and the R region separates the U3 and U5 regions. The transcribed sequence of the R region appears at both the 5' and 3' ends of the viral RNA (see, for example, "RNA Viruses: A Practical Approach" (Alan J. Cann, Ed., Oxford University Press, 2000); O Narayan, J. Gen. Virology. 70: 1617-1639, 1989; Fields et al., Fundamental Virology Raven Press, 1990; Miyoshi et al., J. Virol. 72: 8150-7, 1998; and U.S. Patent No. 6,013,516, each of which is incorporated by reference in its entirety). Optionally, lentiviral vectors can contain any one or more of these elements of the lentiviral genome to regulate the activity of the vector, or can contain deletions, insertions, substitutions, or mutations in one or more of these elements, for example, to reduce the pathological effects of lentiviral replication or limit the lentiviral vector to a single round of infection.

[0194] Typically, a minimal retroviral vector contains certain 5'LTR and 3'LTR sequences, one or more genes of interest (to be expressed in the target cell), one or more promoters, and cis-acting sequences for packaging RNA. Other regulatory sequences described herein and known in the art may be included. Viral vectors are typically cloned into a plasmid that can be transfected into a packaging cell line, such as a eukaryotic cell (e.g., 293-HEK), and typically contains sequences useful for replicating the plasmid in bacteria.

[0195] In certain embodiments, the viral vector comprises sequences derived from the 5' and / or 3' LTR of a retrovirus, e.g., a lentivirus. The LTR sequence can be from any lentivirus of any species. For example, the LTR sequence can be from HIV, SIV, FIV, or BIV. Preferably, the LTR sequence is an HIV LTR sequence. In certain embodiments, the viral vector comprises the R and U5 sequences derived from the 5' LTR of a lentivirus and an inactivated or "self-inactivating" 3' LTR derived from a lentivirus. A "self-inactivating 3' LTR" is a 3' long terminal repeat (LTR) that contains a mutation, substitution, or deletion that prevents the LTR sequence from driving the expression of downstream genes. One copy of the U3 region from the 3' LTR acts as a template for the generation of both LTRs in the integrated provirus. Therefore, when a 3' LTR with an inactivating deletion or mutation is integrated as the 5' LTR of a provirus, transcription from the 5' LTR is impossible. This eliminates the competition between the viral enhancer / promoter and any internal enhancer / promoter. Self-inactivating 3'LTRs are described, for example, in Zufferey et al., J. Virol. 72:9873-9880, 1998; Miyoshi et al., J. Virol. 72:8150-8157, 1998; and Iwakuma et al., J. Virol. 261: 120-132, 1999, each of which is incorporated by reference in its entirety. Self-inactivating 3'LTRs can be generated by any method known in the art. In certain embodiments, the U3 element of the 3'LTR contains a deletion of its enhancer sequence, preferably the TATA box, Spl and / or NF-kappa B site. As a result of the self-inactivating 3'LTR, the provirus integrated into the host cell genome contains an inactivated 5'LTR.

[0196] The vector provided herein typically comprises a gene that encodes a protein (or other molecule, for example, siRNA) that is desired to be expressed in one or more target cells.In viral vectors, the gene of interest is preferably located between the 5'LTR sequence and the 3'LTR sequence.In addition, the gene of interest is preferably functionally associated with other genetic elements, such as transcriptional regulatory sequences, for example, promoters and / or enhancers, so as to regulate the expression of the gene of interest in a specific manner when the gene is incorporated into target cells.In certain embodiments, useful transcriptional regulatory sequences are transcriptional regulatory sequences that are highly regulated in terms of activity both temporally and spatially.

[0197] In some embodiments, one or more additional genes may be incorporated as a safety measure, primarily to enable selective killing of transfected target cells within a heterogeneous population, e.g., within a human subject. In some embodiments, the selected gene is the thymidine kinase gene (TK), the expression of which sensitizes target cells to the action of the drug ganciclovir. In some embodiments, the suicide gene is the caspase-9 suicide gene, which is activated by dimerization drugs (see, e.g., Tey et al., Biology of Blood and Marrow Transplantation 13:913-924, 2007). In certain embodiments, a gene encoding a marker protein is placed before or after the primary gene in a viral or non-viral vector to allow identification and / or selection of cells expressing the desired protein. Certain embodiments incorporate a fluorescent marker protein, e.g., green fluorescent protein (GFP) or red fluorescent protein (RFP), along with the primary gene of interest. If one or more additional reporter genes are included, an IRES sequence or 2A element may also be included, separating the primary gene of interest from the reporter gene and / or any other genes of interest.

[0198] Certain embodiments may employ genes encoding one or more selectable markers. Examples include selectable markers effective in eukaryotic or prokaryotic cells, such as drug resistance genes encoding factors necessary for the survival or growth of transformed host cells grown in selective culture media. Exemplary selectable genes encode proteins that confer resistance to antibiotics or other toxins, such as G418, hygromycin B, puromycin, zeocin, ouabain, blasticidin, ampicillin, neomycin, methotrexate, or tetracycline; complementation or supplementation of auxotrophic deficiencies may be present on a separate plasmid and introduced by cotransfection with a viral vector. In one embodiment, the gene encodes a mutant dihydrofolate reductase (DHFR) that confers methotrexate resistance. Certain other embodiments may use genes encoding one or more cell surface receptors (e.g., low affinity nerve growth factor receptor (LNGFR)) that can be used to tag and detect or purify transfected cells, or other such receptors useful as transduction tag systems. See, e.g., Lauer et al., Cancer Gene Ther. 2000 Mar;7(3):430-7.

[0199] Certain viral vectors, for example, retroviral vectors, use one or more heterologous promoters, enhancers, or both.In some embodiments, the U3 sequence from the 5'LTR of retrovirus or lentivirus can be replaced with promoter or enhancer sequence in viral construct.Some embodiments use the "internal" promoter / enhancer that is located between the 5'LTR sequence and the 3'LTR sequence of viral vector and is operably linked to the gene of interest.

[0200] "Functionally associated" and "operably linked" mean, without limitation, that the gene is in the correct location and orientation relative to the promoter and / or enhancer such that expression of the gene is affected when the promoter and / or enhancer is contacted with the appropriate regulatory molecules. Any enhancer / promoter combination can be used that regulates (e.g., increases, decreases) expression of the viral RNA genome in the packaging cell line, regulates expression of a selected gene of interest in infected target cells, or both.

[0201] A promoter is an expression control element formed by a DNA sequence that allows polymerase binding and transcription to occur. Promoters are untranslated sequences located upstream (5') of the start codon of a selected gene of interest (typically within about 100-1000 bp) that control the transcription and translation of the coding polynucleotide sequence to which they are operably linked. Promoters can be inducible or constitutive. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as a change in temperature. Promoters can be unidirectional or bidirectional. Bidirectional promoters can be used to coexpress two genes, such as a gene of interest and a selectable marker. Alternatively, a bidirectional promoter configuration can be utilized, containing two promoters in opposite orientations in the same vector, each controlling the expression of a different gene.

[0202] A variety of promoters are known in the art, as well as the method for operably linking promoters to polynucleotide coding sequences.Both native promoter sequences and many heterologous promoters can be used to direct the expression of selected target genes.Certain embodiments use heterologous promoters, because they generally allow for more transcription and higher yield of desired proteins compared with native promoters.

[0203] Certain embodiments may use heterologous viral promoters. Examples of such promoters include those obtained from the genomes of viruses such as polyomavirus, fowlpox virus, adenovirus, bovine papillomavirus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). Certain embodiments may use heterologous mammalian promoters, such as actin promoters, immunoglobulin promoters, heat shock promoters, or promoters related to the native sequence of the gene of interest. Typically, the promoter is compatible with target cells, such as activated B lymphocytes, plasma B cells, memory B cells, or other lymphoid target cells.

[0204] Certain embodiments may use one or more RNA polymerase II and III promoters. Suitable selection of RNA polymerase III promoters can be found, for example, in Paule and White. Nucleic Acids Research., Vol. 28, pp. 1283-1298, 2000, the entire contents of which are incorporated by reference. RNA polymerase II and III promoters also include any synthetic or engineered DNA fragment that can direct RNA polymerase II or III, respectively, to transcribe its downstream RNA coding sequence. Furthermore, the RNA polymerase II or III (Pol II or III) promoter(s) used as part of the viral vector can be inducible. Any suitable inducible Pol II or III promoter can be used with the methods described herein. Exemplary Pol II or III promoters include the tetracycline-responsive promoters provided in Ohkawa and Taira, Human Gene Therapy, Vol. 11, pp 577-585, 2000; and Meissner et al, Nucleic Acids Research, Vol. 29, pp 1672-1682, 2001, each of which is incorporated by reference in its entirety.

[0205] Non-limiting examples of constitutive promoters that can be used include the ubiquitin promoter, the CMV promoter (see, e.g., Karasuyama et al., J. Exp. Med. 169: 13, 1989), the β-actin promoter (see, e.g., Gunning et al., PNAS USA 84:4831-4835, 1987), the elongation factor-1 alpha (EF-1 alpha) promoter, the CAG promoter, and the pgk promoter (see, e.g., Adra et al., Gene 60:65-74, 1987; Singer-Sam et al., Gene 32:409-417, 1984; and Dobson et al., Nucleic Acids Res. 10:2635-2637, 1982, each of which is incorporated by reference). Non-limiting examples of tissue-specific promoters include the lck promoter (see, e.g., Garvin et al., Mol. Cell Biol. 8:3058-3064, 1988; and Takadera et al., Mol. Cell Biol. 9:2173-2180, 1989), the myogenin promoter (Yee et al., Genes and Development 7: 1277-1289. 1993), and the thyl promoter (see, e.g., Gundersen et al., Gene 1 13:207-214, 1992).

[0206] Additional examples of promoters include the ubiquitin-C promoter, the human μ heavy chain promoter or Ig heavy chain promoter (e.g., MH), and the human K light chain promoter or Ig light chain promoter (e.g., EEK), which are functional in B lymphocytes. The MH promoter contains a human μ heavy chain promoter preceded by an ιΕμ enhancer flanked by matrix-associated regions, and the EEK promoter contains a κ light chain promoter preceded by an intronic enhancer (ιΕκ), a matrix-associated region, and a 3′ enhancer (3Εκ) (see, e.g., Luo et al., Blood. 1 13: 1422-1431, 2009 and U.S. Patent Application Publication No. 2010 / 0203630). Accordingly, certain embodiments may use one or more of these promoter or enhancer elements.

[0207] In some embodiments, one promoter drives the expression of a selectable marker, and a second promoter drives the expression of a gene of interest. For example, in one embodiment, the EF-1 alpha promoter drives the production of a selectable marker (e.g., DHFR), and a miniature CAG promoter (see, e.g., Fan et al. Human Gene Therapy 10:2273-2285, 1999) drives the expression of a gene of interest (e.g., IDUA). As described above, certain embodiments use enhancer elements, such as internal enhancers, to increase the expression of a gene of interest. Enhancers are cis-acting elements of DNA, usually about 10 to 300 bp in length, that act on a promoter to increase its transcription. Enhancer sequences, such as enhancers, intronic enhancers, and 3' enhancers, can be derived from mammalian genes (e.g., globin, elastase, albumin, α-fetoprotein, insulin). Enhancers derived from eukaryotic viruses are also included, including the SV40 enhancer located on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer located on the late side of the replication origin, and adenovirus enhancers. The enhancer can be spliced ​​into the vector at a position 5' or 3' to the antigen-specific polynucleotide sequence, but is preferably located at a site 5' from the promoter. Those skilled in the art will select an appropriate enhancer based on the desired expression pattern.

[0208] In some embodiments, promoters are selected to allow inducible expression of genes.Several systems for inducible expression are known in the art, including tetracycline-responsive systems and lac operator-repressor systems.It is also contemplated that promoter combinations can be used to obtain the desired expression of target genes.Those skilled in the art can select promoters based on the desired expression pattern of genes in target organisms and / or target cells.

[0209] Certain viral vectors contain cis-acting packaging sequences to facilitate the incorporation of genomic viral RNA into viral particles. Examples include psi sequences. Such cis-acting sequences are known in the art. In certain embodiments, the viral vectors described herein can express two or more genes, which can be achieved, for example, by incorporating an internal promoter operably linked to each separate gene beyond the first gene, by incorporating an element that facilitates coexpression, such as an internal ribosome entry sequence (IRES) element (U.S. Pat. No. 4,937,190, incorporated by reference) or a 2A element, or both. By way of example only, an IRES or 2A element can be used when a single vector contains sequences encoding each chain of an immunoglobulin molecule with the desired specificity. For example, a first coding region (encoding either the heavy or light chain) can be located immediately downstream of the promoter, a second coding region (encoding the other chain) can be located downstream of the first coding region, and an IRES or 2A element is located between the first and second coding regions, preferably immediately preceding the second coding region. In some embodiments, an IRES or 2A element is used to co-express an unrelated gene, such as a reporter gene, a selectable marker, or a gene that enhances immune function. Examples of IRES sequences that can be used include, without limitation, the IRES elements of encephalomyelitis virus (EMCV), foot-and-mouth disease virus (FMDV), Theiler's murine encephalomyelitis virus (TMEV), human rhinovirus (HRV), coxsackievirus (CSV), poliovirus (POLIO), hepatitis A virus (HAV), hepatitis C virus (HCV), and pestiviruses (e.g., hog cholera virus (HOCV) and bovine viral diarrhea virus (BVDV)) (see, e.g., Le et al., Virus Genes 12: 135-147, 1996; and Le et al., Nuc. Acids Res. 25:362-369, 1997, each of which is incorporated by reference in its entirety).An example of a 2A element includes the F2A sequence from foot and mouth disease virus.

[0210] In some embodiments, the vectors provided herein also contain additional genetic elements to achieve a desired result. For example, certain viral vectors may contain a signal, such as an HIV-1 flap signal, that facilitates nuclear entry of the viral genome in target cells. As a further example, certain viral vectors may contain an element, such as a tRNA amber suppressor sequence, that facilitates characterization of the proviral integration site in target cells. Certain viral vectors may contain one or more genetic elements designed to enhance expression of a gene of interest. For example, a woodchuck hepatitis virus responsive element (WRE) may be placed in the construct (see, e.g., Zufferey et al., J. Virol. 74:3668-3681, 1999; and Deglon et al., Hum. Gene Ther. 11:179-190, 2000, each of which is incorporated by reference in its entirety). As another example, a chicken β-globin insulator may also be included in the construct. This element has been shown to reduce the chance of integrated DNA silencing in target cells due to the effects of methylation and heterochromatinization. Furthermore, the insulator can shield internal enhancers, promoters, and exogenous genes from positive or negative positional effects from surrounding DNA at the integration site on the chromosome. Certain embodiments use each of these genetic elements. In another embodiment, the viral vector provided herein can also contain a ubiquitous chromatin opening element (UCOE) to increase expression (see, for example, Zhang F, et al., Molecular Therapy: The Journal of the American Society of Gene Therapy 2010 Sep; 18(9): 1640-9.).

[0211] In some embodiments, the viral vectors provided herein (e.g., retroviruses, lentiviruses) are "pseudotyped" with one or more selected viral glycoproteins or envelope proteins primarily to target selected cell types. Pseudotyping generally refers to the incorporation of one or more heterologous viral glycoproteins onto cell surface viral particles, often allowing the viral particles to infect selected cells that are different from their normal target cells. The "heterologous" elements are derived from a virus other than the virus from which the viral vector's RNA genome is derived. Typically, the glycoprotein coding region of the viral vector is genetically altered, such as by deletion, to prevent expression of its own glycoprotein. By way of example only, the envelope glycoproteins gp41 and / or gp120 from HIV-derived lentiviral vectors are typically removed prior to pseudotyping with heterologous viral glycoproteins.

[0212] In some embodiments, the viral vector is pseudotyped with a heterologous viral glycoprotein that targets B lymphocytes. In some embodiments, the viral glycoprotein allows for selective infection or transduction of resting or quiescent B lymphocytes. In some embodiments, the viral glycoprotein allows for selective infection of B lymphocytes, including plasma cells, plasmablasts, and activated B cells. In some embodiments, the viral glycoprotein allows for infection or transduction of resting B lymphocytes, plasmablasts, plasma cells, and activated B cells. In some embodiments, the viral glycoprotein allows for infection of B cell chronic lymphocyte leukemia cells. In one embodiment, the viral vector is pseudotyped with VSV-G. In some embodiments, the heterologous viral glycoprotein is derived from the glycoprotein of a measles virus, e.g., the Edmonton measles virus. In some embodiments, the measles virus glycoprotein hemagglutinin (H), the fusion protein (F), or both are pseudotyped (see, e.g., Frecha et al., Blood. 1 12:4843-52, 2008; and Frecha et al., Blood. 1 14:3173-80, 2009, each of which is incorporated by reference in its entirety). In some embodiments, the viral vector is pseudotyped with gibbon leukemia virus (GALV). In some embodiments, the viral vector is pseudotyped with feline endogenous retrovirus (RD114). In some embodiments, the viral vector is pseudotyped with baboon endogenous retrovirus (BaEV). In some embodiments, the viral vector is pseudotyped with murine leukemia virus (MLV). In some embodiments, the viral vector comprises an embedded antibody binding domain, e.g., one or more variable regions (e.g., heavy and light chain variable regions), that functions to target the vector to a specific cell type.

[0213] Production of viral vectors can be achieved using any suitable genetic engineering technique known in the art, including, but not limited to, standard techniques of restriction endonuclease digestion, ligation, transformation, plasmid purification, PCR amplification, and DNA sequencing, as described, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY (1989)), Coffin et al. (Retroviruses. Cold Spring Harbor Laboratory Press, NY (1997)), and "RNA Viruses: A Practical Approach" (Alan J. Cann, Ed., Oxford University Press, (2000)).

[0214] Any variety of methods known in the art can be used to produce suitable retroviral particles whose genome contains the RNA copy of viral vector.As one method, viral vector can be introduced into a packaging cell line, which packages viral genomic RNA based on viral vector into viral particles with desired target cell specificity.The packaging cell line typically provides the viral proteins required in trans for packaging viral genomic RNA into viral particles and infecting target cells, including structural protein gag, enzyme protein pol and envelope glycoprotein.

[0215] In some embodiments, the packaging cell line stably expresses certain necessary or desired viral proteins (e.g., gag, pol) (see, e.g., U.S. Patent No. 6,218,181, incorporated herein by reference). In some embodiments, the packaging cell line is transiently transfected with a plasmid encoding certain necessary or desired viral proteins (e.g., gag, pol, glycoproteins), including the measles virus glycoprotein sequences described herein. In some embodiments, the packaging cell line stably expresses the gag and pol sequences, and the cell line is then transfected with a plasmid encoding the viral vector and a plasmid encoding the glycoprotein. After introduction of the desired plasmid, the viral particles are collected and processed accordingly, for example, by ultracentrifugation to obtain a concentrated stock of viral particles. Exemplary packaging cell lines include 293 (ATCC CCL X), HeLa (ATCC CCL 2), D17 (ATCC CCL 183), MDCK (ATCC CCL 34), BHK (ATCC CCL-10), and Cf2Th (ATCC CRL 1430) cell lines.

[0216] In some embodiments, the genetically modified B cells comprise a polynucleotide having a sequence identical to SEQ ID NO: 1. In some embodiments, the genetically modified B cells comprise a polynucleotide having a sequence that is at least about 85% identical to SEQ ID NO: 1, or at least about 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% identical to SEQ ID NO: 1.

[0217] In some embodiments, the genetically modified B cells are engineered on day 2 or 3 after initiation of culture. In some embodiments, the genetically modified B cells are engineered using a method comprising electroporation. In some embodiments, the genetically modified B cells are harvested for administration to a subject on day 4, 5, 6, or 7 of culture after manipulation. In some embodiments, the genetically modified B cells are harvested for administration to a subject on day 8 or later of culture after manipulation. In some embodiments, the genetically modified B cells are harvested for administration to a subject on day 10 or earlier of culture after manipulation.

[0218] In some embodiments, the collected genetically modified B cells do not produce significant levels of inflammatory cytokines. In some embodiments, the genetically modified B cells are collected at a point in culture when it has been determined that they do not produce significant levels of inflammatory cytokines.

[0219] In some embodiments, B cells are contacted with one or more B cell activators, e.g., any of a variety of cytokines, growth factors, or cell lines known to activate and / or differentiate B cells (see, e.g., Fluckiger, et al. Blood 1998 92: 4509-4520; Luo, et al, Blood 2009 1 13: 1422-1431). Such factors include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL -16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL- The chemokines may be selected from, but are not limited to, the group consisting of: IL-31, IL-32, IL-33, IL-34 and IL-35, IFN-γ, IFN-α, IFN-β, IFN-δ, the C-type chemokines XCL1 and XCL2, the CC-type chemokines (which so far include CCL1 to CCL28) and the CXC-type chemokines (which so far include CXCL1 to CXCL17), as well as members of the TNF superfamily (e.g., TNF-α, 4-1 BB ligand, B cell activating factor (BLyS), FAS ligand, sCD40L (multimeric versions of sCD40L; for example, histidine-tagged soluble recombinant CD40L combined with an anti-polyhistidine mAb to group multiple sCD40L molecules together), lymphotoxin, OX40L, RANKL, TRAIL), CpG, and other toll-like receptor agonists.

[0220] B cell activating factors can be added to in vitro cell cultures at various concentrations to achieve a desired outcome (e.g., expansion or differentiation). In some embodiments, B cell activating factors are utilized in expanding B cells in culture. In some embodiments, B cell activating factors are utilized in differentiating B cells in culture. In some embodiments, B cell activating factors are utilized both in expanding and differentiating B cells in culture. In some embodiments, B cell activating factors are provided at the same concentration for expansion and differentiation. In some embodiments, B cell activating factors are provided at a first concentration for expansion and a second concentration for differentiation. It is contemplated that B cell activating factors may 1) be utilized in expanding B cells but not in differentiating B cells, 2) be utilized in differentiating B cells but not in expanding B cells, or 3) be utilized in expanding and differentiating B cells.

[0221] For example, B cells are cultured with one or more B cell activating factors selected from CD40L, IL-2, IL-4, and IL-10 for B cell expansion. In some embodiments, B cells are cultured with 0.25 to 5.0 μg / ml of CD40L. In some embodiments, the concentration of CD40L is 0.5 μg / ml. In one embodiment, a cross-linking agent (e.g., an anti-HIS antibody in combination with HIS-tagged CD40L) is used to create CD40L multimers. In some embodiments, CD40L molecules are covalently linked or held together using a protein multimerization domain (e.g., the Fc region of IgG or a leucine zipper domain). In some embodiments, CD40L is conjugated to beads. In one embodiment, CD40L is expressed from feeder cells. In some embodiments, B cells are cultured with 1 to 10 ng / ml of IL-2. In some embodiments, the concentration of IL-2 is 5 ng / ml. In one embodiment, the B cells are cultured with 1-10 ng / ml of IL-4. In some embodiments, the concentration of IL-4 is 2 ng / ml. In some embodiments, the B cells are cultured with 10-100 ng / ml of IL-10. In some embodiments, the concentration of IL-10 is 40 ng / ml.

[0222] In some embodiments, B cells are cultured with one or more B cell activating factors selected from CD40L, IL-2, IL-4, IL-10, IL-15, and IL-21 for B cell expansion. In some embodiments, B cells are cultured with 0.25 to 5.0 μg / ml of CD40L. In some embodiments, the concentration of CD40L is 0.5 μg / ml. In some embodiments, a cross-linking agent (e.g., an anti-HIS antibody in combination with HIS-tagged CD40L) is used to create CD40L multimers. In some embodiments, CD40L molecules are covalently linked or held together using a protein multimerization domain (e.g., the Fc region of IgG or a leucine zipper domain). In some embodiments, CD40L is conjugated to beads. In one embodiment, CD40L is expressed from feeder cells. In one embodiment, B cells are cultured with 1 to 10 ng / ml of IL-2. In some embodiments, the concentration of IL-2 is 5 ng / ml. In some embodiments, the B cells are cultured with 1-10 ng / ml of IL-4. In some embodiments, the concentration of IL-4 is 2 ng / ml. In one embodiment, the B cells are cultured with 10-100 ng / ml of IL-10. In some embodiments, the concentration of IL-10 is 40 ng / ml. In one embodiment, the B cells are cultured with 50-150 ng / ml of IL-15. In some embodiments, the concentration of IL-15 is 100 ng / ml. In some embodiments, the B cells are cultured with 50-150 ng / ml of IL-21. In some embodiments, the concentration of IL-21 is 100 ng / ml. In some embodiments, the B cells are cultured with CD40L, IL-2, IL-4, IL-10, IL-15, and IL-21 for B cell expansion.

[0223] In some embodiments, the genetically modified B cells are grown in a culture system containing each of IL-2, IL-4, IL-10, IL-15, IL-31, and multimerized CD40 ligand throughout the entire culture period before and after manipulation. In some embodiments, the multimerized CD40 ligand is a HIS-tagged CD40 ligand multimerized using an anti-his antibody.

[0224] For example, in one embodiment, B cells are cultured with B cell activators CD40L, IL-2, IL-4, IL-10, IL-15, and IL-21, and CD40L is crosslinked with a crosslinking agent to create multimers of CD40L for B cell expansion. Such a culture system can be maintained throughout the entire culture period (e.g., a 7-day culture period), at which time the B cells are transfected or otherwise engineered to express a transgene of interest (e.g., an exogenous polypeptide, such as IDUA).

[0225] In another example, B cells are cultured with one or more B cell activating factors selected from CD40L, IFN-α, IL-2, IL-6, IL-10, IL-15, IL-21, and P-class CpG oligodeoxynucleotides (p-ODN) for B cell differentiation. In some embodiments, B cells are cultured with 25-75 ng / ml of CD40L. In some embodiments, the concentration of CD40L is 50 ng / ml. In some embodiments, B cells are cultured with 250-750 U / ml of IFN-α. In some embodiments, the concentration of IFN-α is 500 U / ml. In some embodiments, B cells are cultured with 5-50 U / ml of IL-2. In some embodiments, the concentration of IL-2 is 20 U / ml. In some embodiments, B cells are cultured with 25-75 ng / ml of IL-6. In some embodiments, the concentration of IL-6 is 50 ng / ml. In one embodiment, B cells are cultured with 10 to 100 ng / ml of IL-10. In some embodiments, the concentration of IL-10 is 50 ng / ml. In some embodiments, B cells are cultured with 1 to 20 ng / ml of IL-15. In one embodiment, the concentration of IL-15 is 10 ng / ml. In some embodiments, B cells are cultured with 10 to 100 ng / ml of IL-21. In some embodiments, the concentration of IL-21 is 50 ng / ml. In one embodiment, B cells are cultured with 1 to 50 μg / ml of p-ODN. In some embodiments, the concentration of p-ODN is 10 μg / ml.

[0226] In some embodiments, B cells are contacted or cultured on feeder cells. In some embodiments, the feeder cells are a stromal cell line, for example, murine stromal cell line S17 or MS5. In some embodiments, isolated CD19+ cells are cultured with one or more B cell activating cytokines, for example, IL-10 and IL-4, in the presence of fibroblasts expressing CD40 ligand (CD40L, CD154). In some embodiments, CD40L is provided bound to a surface, for example, a tissue culture plate or beads. In some embodiments, purified B cells are cultured with CD40L and one or more cytokines or factors selected from IL-10, IL-4, IL-7, p-ODN, CpG DNA, IL-2, IL-15, IL-6, IL-21, and IFN-α, with or without feeder cells.

[0227] In some embodiments, B cell activating factors are provided by transfection into B cells or other feeder cells. In this regard, one or more factors that promote B cell differentiation into antibody-secreting cells and / or one or more factors that promote the longevity of antibody-producing cells may be used. Such factors include, for example, Blimp-1, TRF4, anti-apoptotic factors such as Bcl-x1 or Bcl5, or constitutively active mutants of the CD40 receptor. Additionally, factors that promote the expression of downstream signaling molecules, such as TNF receptor-associated factors (TRAFs), may also be used in B cell activation / differentiation. In this regard, the cell activation, cell survival, and anti-apoptotic functions of the TNF receptor superfamily are largely mediated by TRAFs 1-6 (see, e.g., RH Arch, et al., Genes Dev. 12 (1998), pp. 2821-2830). Downstream effectors of TRAF signaling include transcription factors in the NF-KB and AP-1 families, which can turn on genes involved in various aspects of cellular and immune function. Furthermore, activation of NF-κB and AP-1 has been shown to provide cellular protection from apoptosis through the transcription of anti-apoptotic genes.

[0228] In some embodiments, Epstein-Barr virus (EBV) derived proteins are used for B cell activation and / or differentiation or to promote the longevity of antibody-producing cells, including, but not limited to, EBNA-1, EBNA-2, EBNA-3, LMP-1, LMP-2, EBER, miRNA, EBV-EA, EBV-MA, EBV-VCA, and EBV-AN.

[0229] In some embodiments, contacting B cells with a B cell activator using the methods provided herein results in, among other things, cell proliferation (i.e., expansion), modulation of the IgM+ cell surface phenotype to a phenotype consistent with activated mature B cells, Ig secretion, and isotype switching. CD19+ B cells can be isolated using known and commercially available cell separation kits, for example, the MiniMACS™ cell separation system (Miltenyi Biotech, Bergisch Gladbach, Germany). In certain embodiments, CD40L fibroblasts are irradiated prior to use in the methods described herein. In one embodiment, B cells are cultured in the presence of one or more of IL-3, IL-7, Flt3 ligand, thrombopoietin, SCF, IL-2, IL-10, G-CSF, and CpG. In some embodiments, the method involves culturing B cells in the presence of one or more of the above-mentioned factors in conjunction with transformed stromal cells (e.g., MS5) that provide low levels of fixed CD40L and / or plate- or bead-bound CD40L.

[0230] As discussed above, B cell activators induce the expansion, proliferation, or differentiation of B cells. Thus, B cells are contacted with one or more B cell activators listed above to obtain an expanded cell population. The cell population may be expanded prior to transfection. Alternatively, or in addition, the cell population may be expanded after transfection. In one embodiment, expanding the B cell population comprises culturing the cells with IL-2, IL-4, IL-10, and CD40L (see, e.g., Neron et al. PLoS ONE, 2012 7(12):e51946). In one embodiment, expanding the B cell population comprises culturing the cells with IL-2, IL-10, CpG, and CD40L. In one embodiment, expanding the B cell population comprises culturing the cells with IL-2, IL-4, IL-10, IL-15, IL-21, and CD40L. In one embodiment, expanding the B cell population comprises culturing the cells with IL-2, IL-4, IL-10, IL-15, IL-21, and multimerized CD40L.

[0231] In some embodiments, the expansion of B cell populations is induced and / or enhanced by small molecule compounds added to cell culture. For example, compounds that bind to and dimerize CD40 can be used to induce the CD40 signaling pathway.

[0232] Any of a variety of culture media can be used in the methods of the present invention, as known to those skilled in the art (see, for example, Current Protocols in Cell Culture, 2000-2009 by John Wiley & Sons, Inc.). In some embodiments, media for use in the methods described herein include, but are not limited to, Iscove's Modified Dulbecco's Medium (with or without fetal bovine serum or other suitable serum). Exemplary media also include, but are not limited to, IMDM, RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12, X-Vivo 15, and X-Vivo 20. In some embodiments, media can contain detergents, antibodies, plasmanate or reducing agents (e.g., N-acetyl-cysteine, 2-mercaptoethanol), one or more antibiotics, and / or additives, such as insulin, transferrin, sodium selenite, and cyclosporine. In some embodiments, IL-6, soluble CD40L, and cross-linking enhancers can also be used.

[0233] B cells are cultured under conditions and for a sufficient period of time to achieve the desired differentiation and / or activation. In some embodiments, B cells are cultured under conditions and for a sufficient period of time to achieve 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or even 100% of the B cells, as desired. In some embodiments, B cells are activated and differentiated into a mixed population of plasmablasts and plasma cells. As will be appreciated by those skilled in the art, plasmablasts and plasma cells can be identified by standard flow cytometry methods described elsewhere herein, e.g., CD38, CD78, IL-6R, CD27, and the like. highand CD138, and / or lack of or reduced expression of one or more of CD19, CD20, and CD45. As will be appreciated by those skilled in the art, memory B cells are generally CD20+CD19+CD27+CD38-, while early plasmablasts are CD20-CD19+CD27++CD38++. In one embodiment, cells cultured using the methods described herein are CD20-, CD38+, CD138-. In another embodiment, the cells have a CD20-, CD38+, CD138+ phenotype. In certain embodiments, the cells are cultured for 1 to 7 days. In further embodiments, the cells are cultured for 7, 14, 21, or longer days. Thus, cells can be cultured under appropriate conditions for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 days or more. Cells can be replated and media and supplements can be added or replaced as needed using techniques known in the art.

[0234] In some embodiments, the B cells are cultured under conditions, and for a period of time sufficient, such that at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the cells are differentiated and activated to produce Ig and / or express the transgene.

[0235] Induction of B cell activation can be measured by techniques such as H-uridine incorporation into RNA (RNA synthesis increases as B cells differentiate) or by H-thymidine incorporation, which measures DNA synthesis associated with cell proliferation. In some embodiments, interleukin-4 (IL-4) can be added to the culture medium at an appropriate concentration (e.g., about 10 ng / ml) to enhance B cell proliferation.

[0236] Alternatively, B cell activation can be measured as a function of immunoglobulin secretion. For example, CD40L is added to resting B cells along with IL-4 (e.g., 10 ng / ml) and IL-5 (e.g., 5 ng / ml), or other cytokines that activate B cells. Flow cytometry can also be used to measure cell surface markers typical of activated B cells. See, e.g., Civin CI, Loken MR, Int'l J. Cell Cloning 987;5:1-16; Loken, MR, et al, Flow Cytometry Characterization of Erythroid, Lymphoid and Mononomyeloid Lineages in Normal Human Bone Marrow, in Flow Cytometry in Hematology, Laerum OD, Bjerksnes R. eds., Academic Press, New York 1992;pp. 31-42; and LeBein TW, et al, Leukemia 1990;4:354-358.

[0237] After culturing for an appropriate period of time, for example, 2, 3, 4, 5, 6, 7, 8, 9, or more days, typically approximately 3 days, additional amounts of culture medium can be added. Supernatants from individual cultures can be collected at various time points during culture and quantified for IgM and IgG1 as described in Noelle et al. (1991) J. Immunol. 146: 1118-1124. In some embodiments, cultures are harvested and assayed for expression of the transgene of interest using flow cytometry, enzyme-linked immunosorbent assay (ELISA), ELISPOT, or other assays known in the art. In some embodiments, ELISA is used to measure antibody isotype production, e.g., IgM, or the product of the transgene of interest. In some embodiments, IgG determination is performed using a commercially available antibody, e.g., goat anti-human IgG, as a capture antibody, followed by detection using any of a variety of appropriate detection reagents, e.g., biotinylated goat anti-human Ig, streptavidin alkaline phosphatase, and substrate.

[0238] In certain embodiments, B cells are cultured under conditions and for a period of time sufficient to increase the number of cells to 1, 10, 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or more times greater than the number of B cells at the initiation of the culture. In some embodiments, the number of cells is 10 to 1000 times greater than the number of B cells at the initiation of the culture, including consecutive integers therein. For example, the expanded B cell population is at least 10 times greater than the initially isolated B cell population. In another embodiment, the expanded B cell population is at least 100 times greater than the initially isolated B cell population. In some embodiments, the expanded B cell population is at least 500 times greater than the initially isolated B cell population.

[0239] In some embodiments, the method includes expanding the genetically modified B cells prior to administering to the subject.

[0240] In some embodiments, the engineered B cell population is evaluated for polyclonality before administration to a subject. Ensuring the polyclonality of the final cell product is an important safety parameter. Specifically, the emergence of a dominant clone is considered to potentially contribute to in vivo tumorigenesis or autoimmune disease. Polyclonality can be assessed by any means known in the art or described herein. For example, in some embodiments, polyclonality is assessed by sequencing (e.g., by deep sequencing) the B cell receptors expressed in the engineered B cell population. Because B cell receptors undergo changes during B cell development that make them unique among B cells, this method allows for the quantification of how many cells share the same B cell receptor sequence (meaning they are clonal). Thus, in some embodiments, the more B cells in the engineered B cell population express the same B cell receptor sequence, the more clonal the population is, and therefore the less safe the population is for administration to a subject. Conversely, in some embodiments, the fewer B cells in an engineered B cell population that express the same B cell receptor sequence, the less clonal (i.e., more polyclonal) the population will be, and therefore the safer the population will be for administration to a subject.

[0241] In some embodiments, the engineered B cell population is evaluated for polyclonality before administration to a subject. Ensuring the polyclonality of the final cell product is an important safety parameter. Specifically, the emergence of a dominant clone is considered to potentially contribute to in vivo tumorigenesis or autoimmune disease. Polyclonality can be assessed by any means known in the art or described herein. For example, in some embodiments, polyclonality is assessed by sequencing (e.g., by deep sequencing) the B cell receptors expressed in the engineered B cell population. Because B cell receptors undergo changes during B cell development that make them unique among B cells, this method allows for the quantification of how many cells share the same B cell receptor sequence (meaning they are clonal). Thus, in some embodiments, the more B cells in the engineered B cell population express the same B cell receptor sequence, the more clonal the population is, and therefore the less safe the population is for administration to a subject. Conversely, in some embodiments, the fewer B cells in an engineered B cell population that express the same B cell receptor sequence, the less clonal (i.e., more polyclonal) the population will be, and therefore the safer the population will be for administration to a subject.

[0242] In some embodiments, engineered B cells are administered to a subject after it has been determined that they are sufficiently polyclonal. For example, engineered B cells may be administered to a subject after it has been determined that a particular B cell clone in the final population comprises no more than about 0.2% of the total B cell population. Engineered B cells may be administered to a subject after it has been determined that a particular B cell clone in the final population comprises no more than about 0.1% of the total B cell population, or no more than about 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, or no more than about 0.04% of the total B cell population. In certain embodiments, engineered B cells (e.g., IDUA-producing) are administered to a subject after it has been determined that a particular B cell clone in the final population comprises no more than about 0.03% of the total B cell population.

[0243] In some embodiments, the final population of expanded genetically modified B cells demonstrates a high degree of polyclonality. In some embodiments, any particular B cell clone in the final population of expanded genetically modified B cells comprises less than 0.2% of the total B cell population. In some embodiments, any particular B cell clone in the final population of expanded genetically modified B cells comprises less than 0.05% of the total B cell population.

[0244] In some embodiments, the genetically modified B cells comprise a polynucleotide encoding a human DHFR gene with enhanced resistance to methotrexate. In some embodiments, the human DHFR gene with enhanced resistance to methotrexate contains a leucine to tyrosine substitution at amino acid 22 and a phenylalanine to serine substitution at amino acid 31. In some embodiments, the method includes treating the genetically modified B cells with methotrexate prior to harvesting for administration. In some embodiments, the methotrexate treatment is between 100 nM and 300 nM. In some embodiments, the methotrexate treatment is 200 nM.

[0245] In some embodiments, the genetically modified B cells, upon administration to a subject, migrate throughout tissues within the central nervous system (CNS). In some embodiments, administration of the genetically modified B cells to a subject results in a reduction of glycosaminoglycans (GAGs) in various tissues of the subject. In some embodiments, administration of the genetically modified B cells to a subject results in a reduction of GAGs in tissues within the central nervous system (CNS).

[0246] All publications and patents mentioned in this specification are hereby incorporated by reference in their entirety, as if each individual publication or patent was specifically and individually indicated to be incorporated by reference herein. In case of conflict, the present application, including any definitions herein, will control. However, the mention of any references, articles, publications, patents, patent publications, and patent applications cited herein is not, and should not be construed as, an admission or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

[0247] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0248] While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. [Example]

[0249] The present disclosure will now be described with reference to the following examples, which are provided for illustrative purposes only, and the present disclosure should in no way be construed as being limited to these examples, but rather as encompassing any and all variations that become evident as a result of the teachings provided herein.

[0250] Without further description, it is believed that one of ordinary skill in the art can, using the foregoing description and the following illustrative examples, make and utilize the disclosed method and practice the claimed method. Accordingly, the following working examples specifically focus on embodiments of the present disclosure, and are not to be construed as limiting in any way the remainder of the disclosure.

[0251] The materials and methods used in these experiments are now described. Example 1 Administration of engineered B cells to the central nervous system via direct injection into the cerebrospinal fluid background

[0252] Mucopolysaccharidosis type I (MPSI) is a lysosomal storage disease caused by a deficiency in the enzyme alpha-L-iduronidase (IDUA). IDUA catalyzes the breakdown of the glycosaminoglycans (GAGs), heparan sulfate and dermatan sulfate, throughout the body. Deficiency of IDUA leads to the accumulation of GAGs in all tissues, including the brain.

[0253] Current treatments include hematopoietic stem cell transplantation and enzyme replacement. Both restore systemic IDUA activity and reduce peripheral accumulated GAG levels. While these treatments significantly extend life expectancy and improve quality of life, a significant burden of disease remains. In particular, cognitive impairment has proven resistant to treatment, necessitating the development of therapies that directly target the CNS.

[0254] NSG-MPSI mice are immunodeficient and lack IDUA expression, and they recapitulate many of the findings of human MPS1, including lack of IDUA activity and high GAG levels.

[0255] To specifically address the lack of IDUA in the CNS, human B cells genetically engineered to express IDUA were introduced into the lateral ventricles of animals. method

[0256] NSG-MPS I mice (4 months old, n = 6) were injected ICV (in one lateral ventricle) with 2e5 ISP-001 B cells. Mice were euthanized on days 1 (n = 1), 7 (n = 1), 28 (n = 2), and 42 (n = 4) post-injection. Untreated NSG-MPS I mice (n = 2) served as negative controls. Brain tissue was analyzed for IDUA activity and GAG levels. For the IDUA enzyme assay, brain tissue was lysed and assayed for IDUA activity in a fluorometric assay using 4-methylumbelliferyl-alpha-L-iduronide (Glycosynth, England) as a substrate. Protein concentrations of tissue lysates were determined using a Pierce assay system. IDUA activity was recorded as nmol / h / mg protein. For GAG assays, brain lysates were assayed using the Blyscan™ Sulfated Glycosaminoglycan Assay kit (Biocolor Life Science Assays; Accurate Chemical). Tissue GAG ​​content was reported as micrograms of GAG per milligram of protein. result

[0257] Whole brain extracts were assayed for IDUA activity using fluorometric methodology (Figure 1). We observed significant IDUA activity in treated animals compared with control animals. Enzyme activity was highest 7 days after ICV injection but was still detectable at 28 and 42 days.

[0258] Whole brain extracts were assayed for GAG levels (Figure 2). GAG levels in brain tissue were lower in all treated animals compared to control animals. Levels were lowest one day after injection but remained lower than those observed in control animals for the duration of the study. Consideration

[0259] This study demonstrates the delivery of therapeutic B cells to the CNS by infusion into the cerebrospinal fluid (CSF), in this case by ICV injection. IDUA secretion peaked one week after injection, but IDUA levels remained detectable for the duration of the study (6 weeks). The presence of IDUA was also reflected in a significant reduction in GAG levels in the brain. Example 2 Xeno-adoptive transfer of modified human B cells into mice by intracerebroventricular injection method

[0260] Human B cells were transduced in LUC according to standard protocols. NSG mice (n=4, female) were transfected with 3×10 cells isolated from the same donor. 6 CD4+ T cells were injected IP. One week after T cell preconditioning, mice were injected with LUC-transferred human B cells (4 × 10 5 B cells (1000 / ventricle) were injected into both lateral ventricles. B cell engraftment was monitored biweekly by bioluminescence imaging (IVIS). The study was terminated on day 16 (post-B cell injection). result

[0261] Mice were imaged starting 2 days after B cell injection (2 / 26 / 2021) and then biweekly. No adverse effects were observed.

[0262] The results are shown in Figures 3 and 4. Luminescent signals were detected in all animals, but at different times and with different intensities. Mouse 1 generally showed the lowest signal, with the highest signal occurring 13 days after injection. Mouse 2 showed the highest signal in all animals except for the first imaging. The signal increased to its highest level on day 13 and then decreased somewhat. Animal 3 showed a steady increase in luminescence throughout the study, and Mouse 4 showed a steady increase in luminescence after an initial drop on day 6. Luminescent signals in all animals appeared to remain localized to the ventricles, although Mouse 2 showed some signal in the splenic area on day 13. Consideration

[0263] A luminescent signal was detected in the vesicular area throughout the study, indicating successful engraftment of B cells. The signal showed variation between animals but appeared to increase over time, suggesting B cell expansion. This experiment demonstrates that human B cells can be successfully engrafted in the lateral ventricles after intracerebroventricular (ICV) administration to the CNS.

Claims

1. 1. A composition comprising genetically modified B cells for use in a method for the in vivo production of a therapeutic agent, the method comprising: A composition comprising administering one or more doses of genetically modified B cells to the central nervous system (CNS) of a subject.

2. 10. The composition of claim 1, wherein the administering step comprises injection into the cerebrospinal fluid (CSF) of the subject.

3. The composition of claim 2 , wherein the administering step comprises intracisternal injection.

4. The composition of claim 2 , wherein the administering step comprises intrathecal injection.

5. 3. The composition of claim 2, wherein the administering step comprises intracerebroventricular injection (ICV).

6. The composition of claim 5, wherein the intracerebroventricular injection (ICV) is performed in one or more brain cavities.

7. The composition of claim 6 , wherein the one or more brain cavities are the lateral ventricles.

8. The composition of claim 6 , wherein the one or more brain cavities is the third ventricle.

9. The composition of claim 6, wherein the one or more brain cavities is the cerebral aqueduct.

10. The composition of claim 6 , wherein the one or more brain cavities is the fourth ventricle.

11. 2. The composition of claim 1, wherein the therapeutic agent produced by the genetically modified B cells is iduronidase (IDUA).

12. The dose comprises a suboptimal single dose concentration of the genetically modified B cells, the suboptimal single dose concentration being (i) testing multiple single doses of the modified B cells; (ii) determining an optimal single dose concentration of the modified B cells, increasing the dosage of modified B cells present at a single dose concentration of modified B cells results in said production of said therapeutic agent; (iii) testing multiple suboptimal single dose concentrations of the modified B cells; and (iv) determining a suboptimal single dose of the modified B cells, The resulting dose provides greater than linear increase over the lower doses, said suboptimal single dose concentration being less than or equal to about one-half or about one-third the dose of said optimal single dose concentration; The composition of claim 1, wherein the composition is determined by:

13. 2. The composition of claim 1, wherein the administering step optionally comprises one or more sequential doses of the genetically modified B cells.

14. The composition of claim 1 , wherein the subject is a mammal.

15. The composition of claim 1 , wherein the subject is a human.

16. The composition of claim 1 , wherein the genetically modified B cells are autologous to the subject.

17. The composition of claim 1 , wherein the genetically modified B cells are allogeneic to the subject.

18. The composition of claim 1 , wherein the therapeutic agent is a protein.

19. The composition of claim 18 , wherein the protein is an enzyme.

20. The composition of claim 1, wherein the genetically modified B cells are CD20-, CD38+ and CD138+.

21. The composition of claim 1, wherein the genetically modified B cells are CD20-, CD38+ and CD138-.

22. 2. The composition of claim 1, wherein the genetically modified B cells are prepared using a Sleeping Beauty transposon to express the therapeutic agent in the B cells.

23. 2. The composition of claim 1, wherein the genetically modified B cells are prepared using a recombinant viral vector to express the therapeutic agent in the B cells.

24. 24. The composition of claim 23, wherein the recombinant viral vector encodes a recombinant retrovirus, lentivirus, adenovirus, or adeno-associated virus.

25. 2. The composition of claim 1, wherein the genetically modified B cell is prepared by gene editing of the genome of the B cell or by targeted integration of a polynucleotide sequence encoding the therapeutic agent into the genome of the B cell.

26. 26. The composition of claim 25, wherein the targeted integration comprises zinc finger nuclease-mediated gene integration, CRISPR-mediated gene integration or gene editing, TALE-nuclease-mediated gene integration, or meganuclease-mediated gene integration.

27. The composition of claim 26, wherein the targeted integration of the polynucleotide is by homologous recombination.

28. The composition of claim 25, wherein the targeted integration comprises a viral vector-mediated delivery of a nuclease capable of inducing DNA cleavage at a target site.

29. 29. The composition of claim 28, wherein the nuclease is a zinc finger nuclease, a Cas nuclease, a TALE-nuclease or a meganuclease.

30. 30. The composition of any one of claims 1 to 29, wherein the genetically modified B cell comprises a polynucleotide having a sequence identical to SEQ ID NO:

1.

31. 30. The composition of any one of claims 1 to 29, wherein the genetically modified B cell comprises a polynucleotide having a sequence that is at least about 85% identical to SEQ ID NO:1, or at least about 90%, 95%, 96%, 97%, 98%, 99%, or more than 99% identical to SEQ ID NO:

1.

32. 32. The composition of any one of claims 1 to 31, wherein the genetically modified B cells are engineered on day 2 or 3 after initiation of culture.

33. The composition of claim 32, wherein the genetically modified B cells are engineered using a method comprising electroporation.

34. 34. The composition of any one of claims 1-33, wherein the genetically modified B cells are harvested on day 4, 5, 6 or 7 of culture after manipulation for administration to a subject.

35. 34. The composition of any one of claims 1 to 33, wherein the genetically modified B cells are harvested after day 8 or more in culture after manipulation for administration to a subject.

36. 36. The composition of claim 35, wherein the genetically modified B cells are harvested for administration to a subject at or before day 10 in culture after manipulation.

37. 37. The composition of any one of claims 1 to 36, wherein the harvested genetically modified B cells do not produce significant levels of proinflammatory cytokines.

38. 37. The composition of any one of claims 1-36, wherein the genetically modified B cells are harvested at a point in culture where it has been determined that they do not produce significant levels of proinflammatory cytokines.

39. 39. The composition of any one of claims 1 to 38, wherein the genetically modified B cells are grown in a culture system comprising each of IL-2, IL-4, IL-10, IL-15, IL-21, and multimerized CD40 ligand throughout the entire culture period before and after manipulation.

40. 40. The composition of claim 39, wherein the multimerized CD40 ligand is a HIS-tagged CD40 ligand multimerized using an anti-his antibody.

41. The composition of any one of claims 1 to 40, wherein the method further comprises a step of expanding the genetically modified B cells prior to the step of administering to the subject.

42. 42. The composition of claim 41, wherein the final population of expanded genetically modified B cells exhibits a high degree of polyclonality.

43. 42. The composition of claim 41, wherein any particular B cell clone in said final population of expanded genetically modified B cells comprises less than 0.2% of the total B cell population.

44. 42. The composition of claim 41, wherein any particular B cell clone in said final population of expanded genetically modified B cells comprises less than 0.05% of the total B cell population.

45. 45. The composition of any one of claims 1 to 44, wherein the genetically modified B cells comprise a polynucleotide encoding a human DHFR gene that has enhanced resistance to methotrexate.

46. 46. ​​The composition of claim 45, wherein the human DHFR gene having enhanced resistance to methotrexate contains a leucine to tyrosine substitution at amino acid 22 and a phenylalanine to serine substitution at amino acid 31.

47. The composition of any one of claims 1 to 46, wherein the method comprises treating the genetically modified B cells with methotrexate prior to collection for administration.

48. 48. The composition of claim 47, wherein the methotrexate treatment is between 100 nM and 300 nM.

49. 49. The composition of claim 48, wherein the methotrexate treatment is 200 nM.

50. 50. The composition of any one of claims 1-49, wherein the genetically modified B cells migrate throughout tissues within the central nervous system (CNS) upon administration to the subject.

51. 51. The composition of claim 50, wherein said administration of said composition to said subject results in a reduction of glycosaminoglycans (GAGs) in various tissues of said subject.

52. 52. The composition of claim 51, wherein said administration of said composition to said subject results in a reduction of GAGs in tissues within the central nervous system (CNS).

53. 53. The composition of any one of claims 1-52, wherein the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after administration.

54. 53. The composition of any one of claims 1-52, wherein the genetically modified B cells persist in the central nervous system (CNS) for at least about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after administration.

55. 53. The composition of any one of claims 1-52, wherein the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after administration.

56. 53. The composition of any one of claims 1-52, wherein the genetically modified B cells persist in the central nervous system (CNS) for up to about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after administration.

57. 57. The composition of any one of claims 1 to 56, wherein the subject has a disease or disorder associated with lysosomal storage dysfunction.

58. 58. The composition of claim 57, wherein the disease or disorder associated with lysosomal storage dysfunction is caused by an enzyme alpha-L-iduronidase (IDUA) deficiency.

59. 58. The composition of claim 57, wherein the subject has Mucopolysaccharidosis Type I (MPS I).

60. 60. The composition of any one of claims 57 to 59, wherein said administration of said composition treats a disease or disorder associated with lysosomal storage dysfunction in said subject.

61. 60. The composition of claim 59, wherein said administration of said composition treats MPS I in said subject.